Cocrystals of substituted glycine compounds and uses thereof

Abstract

To identify suitable coformers (e.g., tartaric acid and fumaric acid) for producing desirable co-crystals of substituted glycine compounds (e.g., N-methylglycine), of which at least some have a suitable substituted glycine compound:coformer ratio (e.g., 1:1, 2:1, 3:1, or 6:1), the co-crystals exhibiting unexpectedly improved properties such as hygroscopicity, processability and water solubility.SOLUTION: Accordingly, the present disclosure provides a co-crystal of a substituted glycine compound and a coformer of formula (I), a composition comprising the same, and uses thereof to treat and / or reduce the risk of neuropsychiatric disorders (e.g., schizophrenia, psychosis, depressive disorders, suicidal ideation and / or behavior, obsessive-compulsive disorder or Alzheimer's disease). Also provided is a method for preparing the co-crystal.SELECTED DRAWING: None

Description

[Technical Field]

[0001] This application claims priority to U.S. Non-Provisional Application No. 15 / 430,750, filed February 13, 2017, which is incorporated herein by reference. [Background technology]

[0002] Cocrystals are homogeneous multicomponent systems that contain at least one pharmaceutical substance (e.g., an active ingredient) and at least one coformer, which are conjugated together by a supramolecular synthon. Medicinal cocrystals have attracted considerable interest because of their contribution to improving potentially advantageous physicochemical properties of pharmaceutical substances, such as solubility, dissolution rate, bioavailability, physical and / or chemical stability, flowability, hygroscopicity, processability, etc. Furthermore, minimizing the hygroscopicity of pharmaceutical substances can be one of the most challenging tasks in pharmaceutical development and manufacturing. Summary of the Invention [Problem to be solved by the invention]

[0003] During the cocrystal development stage, suitable coformers for producing drug cocrystals of a particular drug substance are typically identified by a trial-and-error approach. Thus, the selection of a suitable coformer for a drug substance to produce a desired drug cocrystal, the selection of the ratio of the drug substance to the coformer, and the method for producing such a cocrystal are major challenges in producing drug cocrystals for a particular drug substance. [Means for solving the problem]

[0004] The present disclosure is based, at least in part, on the identification of suitable coformers (e.g., tartaric acid and fumaric acid) for producing desirable cocrystals of substituted glycine compounds (e.g., N-methylglycine) with appropriate substituted glycine compound:coformer ratios (e.g., 1:1, 2:1, 3:1, or 6:1). Such cocrystals exhibit unexpectedly improved properties, such as hygroscopicity, processability, and aqueous solubility.

[0005] Accordingly, provided herein are co-crystals of a substituted glycine compound and a co-former, wherein the co-former is a compound of Formula (I) as described herein, compositions and kits comprising such co-crystals, methods for making such co-crystals, and uses of the co-crystals for treating and / or reducing the risk of a neuropsychiatric disorder (e.g., schizophrenia, psychosis, pain, or Alzheimer's disease).

[0006] In one aspect, the present disclosure provides a co-crystal of a substituted glycine compound (e.g., N-methylglycine, N-dimethylglycine, N-trimethylglycine, etc.) with a coformer, wherein the coformer is a compound of formula (I):

[0007] [ka]

[0008] [Here A and B are independently OH or H; W is O or NH; X is H or absent; Y is C=O or CR1R2, where R1 and R2 are independently selected from H, alkyl, alkenyl, or alkynyl; Z is OH or —CH(OH)R3, where the C atom of —CH(OH)R3 is in the (R)-configuration and R3 is H or alkyl; and

[0009] [ka]

[0010] is C2-C1 or C2=C1, where C1 and C2 are SP 3 or SP 2 and when X is absent and either R1 or R2 is absent, Y and W can be joined by a single bond. The molar ratio between the substituted glycine and the coformer in the cocrystals described herein can range from 6:1 to 1:5, for example, from 6:1 to 1:1.

[0011] [ka]

[0012] When is C2-C1, the molar ratio between the substituted glycine and the coformer in the cocrystal can range from 1:1 to 1:5.

[0013] In one aspect, the disclosure provides a co-crystal of a substituted glycine compound and a coformer, wherein the coformer is a compound of formula (I):

[0014] [ka]

[0015] [Here A and B are each independently OH or H; W is O or NH; X is H or absent; Y is C=O or CR1R2, where R1 and R2 are independently selected from H, alkyl, alkenyl, or alkynyl; Z is OH or -CH(OH)R3, where the C atom of -CH(OH)R3 is in the (R)-configuration and R3 is H or alkyl;

[0016] [ka]

[0017] is C2-C1 or C2=C1, where C1 and C2 are SP 3 or SP 2 and when X is absent and either R1 or R2 is absent, Y and W can be joined by a single bond. providing a cocrystal, wherein the molar ratio between the substituted glycine compound and the coformer in the cocrystal is within the range of 6:1 to 1:1. In some embodiments, the coformer compound of formula (I) has formula (IA):

[0018] [ka]

[0019] where

[0020] [ka]

[0021] and Z is as previously described. In one example, the compound of formula (IA) is a tartaric acid, including L-tartaric acid, D-tartaric acid, or DL-tartaric acid:

[0022] [ka]

[0023] In some instances, the molar ratio between the substituted glycine and the coformer can be 1:1 or 2:1. In some embodiments, the coformer compound of formula (I) has formula (IB):

[0024] [ka]

[0025] where

[0026] [ka]

[0027] , A, B, W, X and Z are as previously defined.

[0028] [ka]

[0029] can be C2=C1; A, B or both can be hydrogen; W can be O; and / or X can be H. In one example, the compound of formula II is fumaric acid:

[0030] [ka]

[0031] In some instances, the molecular ratio between the substituted glycine and the coformer can be in the range of 1:2 to 6:1 (e.g., 1:1, 2:1, 3:1, or 6:1). In some instances, the molecular ratio between the substituted glycine and the coformer can be in the range of 6:1 to 1:1. In some instances, the molecular ratio between the substituted glycine and the coformer can be in the range of 3:1 to 1:1. In some instances, the molecular ratio between the substituted glycine and the coformer can be in the range of 2:1 to 1:1. In some instances, the molecular ratio between the substituted glycine and the coformer is 2:1 or 1:1. In some instances, the molecular ratio between the substituted glycine and the coformer is 6:1, 3:1, 2:1, or 1:1. In some embodiments, the coformer compound of formula (I) has the formula (IC):

[0032] [ka]

[0033] wherein C, C, and Z are as previously described. In some embodiments, Z is -CH(OH)R, wherein the C atom is in the (R)-configuration and R is H or alkyl (e.g., alkyl substituted with OH, e.g., CHOH). In one example, the compound of formula (IC) is erythorbic acid:

[0034] [ka]

[0035] In some instances, the molar ratio between the substituted glycine and the coformer can be 1:1. In any of the co-crystals described herein, the substituted glycine compound can be N-methylglycine (also known as sarcosine), N-dimethylglycine, or N-trimethylglycine. In some examples, the substituted glycine compound can be N-methylglycine.

[0036] In particular examples of co-crystals described herein, (i) the substituted glycine is N-methylglycine and the coformer is D-tartaric acid, the ratio of N-methylglycine to D-tartaric acid in the cocrystal is 1:1, and optionally the cocrystal has a powder X-ray diffraction pattern substantially as depicted in FIG. 2 and an endothermic peak corresponding to a melting point of about 139° C.; (ii) the substituted glycine is N-methylglycine and the coformer is L-tartaric acid, the ratio of N-methylglycine to L-tartaric acid in the co-crystal is 1:1, and optionally the co-crystal has a powder X-ray diffraction pattern substantially as depicted in FIG. 6 and an endothermic peak corresponding to a melting point of about 138° C.; (iii) the substituted glycine is N-methylglycine and the coformer is DL-tartaric acid, the ratio of N-methylglycine to DL-tartaric acid in the co-crystal is 1:1, and optionally the co-crystal has a powder X-ray diffraction pattern substantially as depicted in FIG. 10 and an endothermic peak corresponding to a melting point of about 120° C.;

[0037] (iv) the substituted glycine is N-methylglycine, the coformer is fumaric acid, the ratio of N-methylglycine to fumaric acid in the co-crystal is 1:1, and optionally the co-crystal has a powder X-ray diffraction pattern substantially as depicted in FIG. 20; (v) the substituted glycine is N-methylglycine, the coformer is fumaric acid, the ratio of N-methylglycine to fumaric acid in the co-crystal is 2:1, and optionally the co-crystal has a powder X-ray diffraction pattern substantially as depicted in FIG. 21 ; (vi) the substituted glycine is N-methylglycine and the coformer is fumaric acid, the ratio of N-methylglycine to fumaric acid in the co-crystal is 3:1, and optionally the co-crystal has a powder X-ray diffraction pattern substantially as depicted in Figure 22; or (vii) the substituted glycine is N-methylglycine and the coformer is fumaric acid, wherein the ratio of N-methylglycine to fumaric acid in the co-crystal is 6:1, and optionally the co-crystal has a powder X-ray diffraction pattern substantially as depicted in Figure 23.

[0038] In one example, the co-crystal is wherein the substituted glycine compound is N-methylglycine, wherein the molecular ratio between the substituted glycine compound and the coformer in the co-crystal is 1:1, and wherein the co-crystal has a powder X-ray diffraction pattern substantially as depicted in Figure 20. In one example, the co-crystal is wherein the substituted glycine compound is N-methylglycine, wherein the molecular ratio between the substituted glycine compound and the coformer in the co-crystal is 2:1, and wherein the co-crystal has a powder X-ray diffraction pattern substantially as depicted in Figure 21. In one example, the co-crystal is wherein the molecular ratio between the substituted glycine compound and the coformer is 3:1, and wherein the co-crystal has a powder X-ray diffraction pattern substantially as depicted in Figure 22. In one example, the co-crystal is wherein the molecular ratio between the substituted glycine compound and the coformer is 6:1, and wherein the co-crystal has a powder X-ray diffraction pattern substantially as depicted in Figure 23.

[0039] In another aspect, the present invention provides compositions comprising an effective amount of one or more cocrystals described herein and a carrier. In some embodiments, the compositions described herein are pharmaceutical compositions comprising a pharmaceutically acceptable carrier. In some embodiments, the compositions described herein are nutraceutical compositions. In some embodiments, the compositions described herein are health foods. In some embodiments, the compositions described herein are medical foods. All of the compositions described herein comprise an effective amount of a cocrystal described herein. The effective amount can be a therapeutically effective amount or a prophylactically effective amount.

[0040] In another aspect, the present disclosure provides methods for treating and / or reducing the risk of a neuropsychiatric disorder (i.e., a central nervous system (CNS) disorder, such as schizophrenia, psychosis, depression, suicidal thoughts and / or behavior, pain, Alzheimer's disease, or dementia), comprising administering to a subject in need of treatment an effective amount of any of the compositions of the present invention. In another aspect, the present disclosure provides methods for treating and / or reducing the risk of, for example, obesity, hypertension, or disorders of glucose or lipid metabolism, comprising administering to a subject in need of treatment an effective amount of a composition of the present invention.

[0041] Target neuropsychiatric disorders include, but are not limited to, schizophrenia, psychosis, Alzheimer's disease, dementia, frontotemporal dementia, mild cognitive impairment, benign amnesia, closed head injury, autism spectrum disorder (e.g., Asperger's syndrome), attention deficit hyperactivity disorder, obsessive-compulsive disorder, tic disorder, childhood learning disability, premenstrual syndrome, depression, suicidal ideation and / or behavior, dysthymic disorder, bipolar disorder, anxiety disorder, post-traumatic stress disorder, chronic pain, eating disorders, addictive disorders, personality disorders, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis.

[0042] Targeted glucose or lipid metabolism disorders include, but are not limited to, obesity, hypertension, diabetes, hypercholesterolemia, or hyperlipidemia.

[0043] In any of the therapeutic methods described herein, the subject being treated can be a mammal (e.g., a human or non-human mammal). For example, the subject is a human patient having or suspected of having a target disease as described herein.

[0044] Another aspect of the present disclosure relates to a kit comprising a container containing a cocrystal or composition thereof described herein. The kits described herein may contain single or multiple doses of the cocrystal or composition. The kits are useful in the methods of the present disclosure. In some embodiments, the kits further comprise instructions for using the cocrystal or composition.

[0045] In yet another aspect, the present disclosure provides cocrystals and compositions described herein for use in treating and / or reducing the risk of a neuropsychiatric disorder or a disorder of glucose or lipid metabolism as described herein, and / or for use in manufacturing a medicament for use in treating a target disease. In some examples, compositions for use in treating and / or reducing the risk of a neuropsychiatric disorder in a subject are provided, wherein the composition comprises a therapeutically effective amount of a cocrystal of the invention. In some examples, use of a therapeutically effective amount of a cocrystal and composition of the invention for manufacturing a medicament for use in treating or reducing the risk of a neuropsychiatric disorder is provided.

[0046] Details of one or more aspects of the disclosure are provided below. Other features, objects, and advantages of the disclosure will be apparent from the detailed description, examples, and claims. [Definition]

[0047] The definitions of specific functional groups and chemical terms are described in detail below. Chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition (book cover), and specific functional groups are generally defined as described herein. Furthermore, the general theory of organic chemistry, as well as specific functional groups and reactivity, can be found in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith & March, March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987. The present disclosure is not limited in any way by the exemplary substituents described herein.

[0048] The compounds described herein may have one or more asymmetric centers and therefore may exist in various isomeric forms, such as enantiomers and / or diastereomers. For example, the compounds described herein may exist in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of mixtures of stereoisomers, such as racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods well known to those skilled in the art, such as chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; alternatively, preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, ed., University of Notre Dame Press, Notre Dame, IN 1972). The present disclosure further encompasses the compounds of the present invention as individual isomers substantially free of other isomers or as mixtures of various isomers.

[0049] When a range of values is recited, it is intended to encompass each value and subrange within that range. For example, "C 1-6 ” is C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4, C 4-6 , C 4-5 , and C 5-6 It is intended to encompass:

[0050] The term "aliphatic" encompasses both saturated and unsaturated straight-chain (i.e., unbranched), branched, acyclic, cyclic, or polycyclic aliphatic hydrocarbons, which may optionally be substituted with one or more functional groups. As will be understood by those skilled in the art, "aliphatic" is intended to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl groups. Thus, the term "alkyl" includes straight-chain, branched, and cyclic alkyl groups. A similar definition applies to other generic terms, such as "alkenyl," "alkynyl," and the like. Furthermore, the terms "alkyl," "alkenyl," "alkynyl," and the like, encompass both substituted and unsubstituted groups. In certain embodiments, "lower alkyl" is used to refer to alkyl groups (cyclic, acyclic, substituted, unsubstituted, branched, or unbranched) having 1 to 6 carbon atoms.

[0051] In certain embodiments, the alkyl, alkenyl, and alkynyl groups used in this disclosure contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups used in this disclosure contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups used in this disclosure contain 1-8 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups used in this disclosure contain 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups used in this disclosure contain 1-4 carbon atoms. Exemplary aliphatic groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, -CH-cyclopropyl, vinyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclobutyl, -CH-cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, cyclopentyl, -CH-cyclopentyl, n-hexyl, sec-hexyl, cyclohexyl, -CH-cyclohexyl groups, and the like, which in turn may bear one or more substituents. Alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.

[0052] The term "alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 10 carbon atoms ("C 1-10 In some embodiments, an alkyl group has 1 to 9 carbon atoms ("C 1-9 In some embodiments, the alkyl group has 1 to 8 carbon atoms ("C 1-8 In some embodiments, the alkyl group has 1 to 7 carbon atoms ("C 1-7 In some embodiments, the alkyl group has 1 to 6 carbon atoms ("C 1-6In some embodiments, the alkyl group has 1 to 5 carbon atoms ("C 1-5 In some embodiments, the alkyl group has 1 to 4 carbon atoms ("C 1-4 In some embodiments, the alkyl group has 1 to 3 carbon atoms ("C 1-3 In some embodiments, the alkyl group has 1 to 2 carbon atoms ("C 1-2 In some embodiments, the alkyl group has 1 carbon atom ("C alkyl"). In some embodiments, the alkyl group has 2 to 6 carbon atoms ("C 2-6 alkyl). C 1-6 Examples of alkyl groups are methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C5) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), and hexyl (C6) (e.g., n-hexyl). Further examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted ("unsubstituted alkyl") or substituted ("substituted alkyl") with one or more substituents (e.g., halogen such as F or -OH). In certain embodiments, an alkyl group is an unsubstituted C 1-10 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, the alkyl group is a substituted C 1-10 Alkyl (e.g., substituted C 1-6 Alkyl or substituted C 1-3 alkyl, for example, —CF or —CHOH).

[0053] "Alkenyl" refers to a straight or branched chain hydrocarbon group containing 2 to 20 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds ("C 2-20In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C 2-10 In some embodiments, the alkenyl group has 2 to 9 carbon atoms ("C 2-9 In some embodiments, the alkenyl group has 2 to 8 carbon atoms ("C 2-8 In some embodiments, the alkenyl group has 2 to 7 carbon atoms ("C 2-7 In some embodiments, the alkenyl group has 2 to 6 carbon atoms (C 2-6 In some embodiments, the alkenyl group has 2 to 5 carbon atoms ("C 2-5 In some embodiments, the alkenyl group has 2 to 4 carbon atoms ("C 2-4 In some embodiments, the alkenyl group has 2 to 3 carbon atoms ("C 2-3 In some embodiments, the alkenyl group has two carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds may be internal (e.g., as in 2-butenyl) or terminal (e.g., as in 1-butenyl). C 2-4 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. 2-6 Examples of alkenyl groups include the above-mentioned C 2-4 Alkenyl groups include pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl groups include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group independently may be optionally substituted, i.e., unsubstituted ("unsubstituted alkenyl") or substituted ("substituted alkenyl") with one or more substituents. In certain embodiments, an alkenyl group is an unsubstituted C 2-10 In certain embodiments, the alkenyl group is a substituted C2-10 In an alkenyl group, a C=C double bond with unspecified stereochemistry (e.g., -CH=CHCH3 or

[0054] [ka]

[0055] ) can be an (E) or a (Z)-double bond.

[0056] "Alkynyl" refers to a straight-chain or branched hydrocarbon group having 2 to 20 carbon atoms, one or more carbon-carbon triple bonds, and optionally one or more double bonds ("C 2-20 In some embodiments, an alkynyl group has 2 to 10 carbon atoms ("C 2-10 In some embodiments, an alkynyl group has 2 to 9 carbon atoms ("C 2-9 In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C 2-8 In some embodiments, an alkynyl group has 2 to 7 carbon atoms ("C 2-7 In some embodiments, an alkynyl group has 2 to 6 carbon atoms ("C 2-6 In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C 2-5 In some embodiments, an alkynyl group has 2 to 4 carbon atoms ("C 2-4 In some embodiments, an alkynyl group has 2 to 3 carbon atoms ("C 2-3 In some embodiments, the alkynyl group has two carbon atoms ("C2 alkynyl"). The one or more carbon-carbon triple bonds may be internal (e.g., as in 2-butynyl) or terminal (e.g., as in 1-butynyl). C 2-4Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. 2-6 Examples of alkynyl groups include the above-mentioned C 2-4 Alkynyl groups include pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl groups are heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each example of an alkynyl group is independently optionally substituted with one or more substituents, i.e., unsubstituted ("unsubstituted alkynyl") or substituted ("substituted alkynyl"). In certain embodiments, an alkynyl group is an unsubstituted C 2-10 In certain embodiments, the alkynyl group is a substituted C 2-10 It is alkynyl.

[0057] "Carbocyclyl" or "carbocycle" refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms and 0 heteroatoms in a non-aromatic ring system ("C 3-10 In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, the carbocyclyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, the carbocyclyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, the carbocyclyl group has 5 to 10 ring carbon atoms ("C 5-10 carbocyclyl). Typical C 3-6 Carbocyclyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C 3-8 The carbocyclyl group includes, but is not limited to, the above-mentioned C 3-6Examples include carbocyclyl groups, as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C 3-10 The carbocyclyl group includes, but is not limited to, the above-mentioned C 3-8 Carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ) and the like. As the above examples illustrate, in certain embodiments, a carbocyclyl group is a single ring ("monocyclic carbocyclyl") or comprises a fused, bridged, or spiro ring system, e.g., a bicyclic ring system ("bicyclic carbocyclyl"), and can be saturated or partially unsaturated. "Carbocyclyl" includes ring systems in which a carbocycle, as defined above, is fused with one or more aryl or heteroaryl groups, where the point of attachment is on the carbocycle, and in such cases, the number of carbons continues to represent the number of carbons in the carbocyclyl system. Unless otherwise specified, the carbocyclyl group in each instance is independently optionally substituted with one or more substituents, i.e., unsubstituted ("unsubstituted carbocyclyl") or substituted ("substituted carbocyclyl"). In certain embodiments, a carbocyclyl group is an unsubstituted C 3-10 In certain embodiments, the carbocyclyl group is substituted 3-10 It is a carbocyclyl.

[0058] In some embodiments, "carbocyclyl" refers to a monocyclic saturated carbocyclyl group having 3 to 10 carbon atoms ("C 3-10 In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C 3-8In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C 5-6 In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C 5-10 Cycloalkyl). C 5-6 Examples of cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C6). 3-6 Examples of cycloalkyl groups include the C 5-6 Includes cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). 3-8 Examples of cycloalkyl groups include the C 3-6 Cycloalkyl groups include cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each example of a cycloalkyl group is optionally unsubstituted ("unsubstituted cycloalkyl") or substituted ("substituted cycloalkyl") with one or more substituents. In certain embodiments, a cycloalkyl group is an unsubstituted C 3-10 In certain embodiments, the cycloalkyl group is a substituted C 3-10 It is cycloalkyl.

[0059] "Heterocyclyl" or "heterocyclic" refers to a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (a "3- to 10-membered heterocyclyl"). In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment can be at a carbon or nitrogen atom, valence permitting. Heterocyclyl groups can be either monocyclic (a "monocyclic heterocyclyl") or fused, bridged, or spiro ring systems, e.g., bicyclic ring systems (a "bicyclic heterocyclyl"), and can be saturated or partially unsaturated. Heterocyclyl bicyclic ring systems can contain one or more heteroatoms in one or both rings. "Heterocyclyl" refers to a heterocycle, as defined above, fused to one or more carbocyclyl groups, where the point of attachment is on either the carbocycle or the heterocycle, or a heterocycle, as defined above, fused to one or more aryl or heteroaryl groups, where the point of attachment is on the heterocycle, and in such cases the number of ring members continues to represent the number of ring members in the heterocycle system. Unless otherwise specified, the heterocyclyl in each instance may independently be optionally substituted with one or more substituents, i.e., unsubstituted ("unsubstituted heterocyclyl") or substituted ("substituted heterocyclyl"). In certain embodiments, the heterocyclyl group is a 3- to 10-membered unsubstituted heterocyclyl. In certain embodiments, the heterocyclyl group is a 3- to 10-membered substituted heterocyclyl.

[0060] In some embodiments, a heterocyclyl group is a 5- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (a "5- to 10-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- to 8-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur (a "5- to 8-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur (a "5- to 6-membered heterocyclyl"). In some embodiments, a 5- to 6-membered heterocyclyl has 1 to 3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heterocyclyl has 1 to 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur, hi some embodiments, the 5- to 6-membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0061] Typical 3-membered heterocyclyl groups containing one heteroatom include, but are not limited to, aziridinyl, oxiranyl, and thiiranyl. Typical 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Typical 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Typical 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Typical 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Typical 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Typical 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Typical 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, triazinanyl. Typical 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Typical 8-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups (also referred to as 5,6-bicyclic heterocycles) fused to a C6 aryl ring include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, etc. Exemplary 6-membered heterocyclyl groups (also referred to as 6,6-bicyclic heterocycles) fused to an aryl ring include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.

[0062] "Aryl" refers to a group of monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring systems (e.g., 6, 10, or 14 shared pi electrons arranged in a ring) having 6 to 14 ring carbon atoms and 0 heteroatoms in the aromatic ring system ("C 6-14 In some embodiments, an aryl group has 6 ring carbon atoms ("C aryl", e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 aryl," e.g., naphthyl, e.g., 1-naphthyl and 2-naphthyl). In some embodiments, the aryl group has 14 ring carbon atoms ("C 14 "Aryl" (e.g., anthracyl). "Aryl" also encompasses ring systems in which an aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups, where the residue or point of attachment is on the aryl ring, and in such cases, the number of carbon atoms continues to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of the aryl group independently may be optionally substituted with one or more substituents, i.e., unsubstituted ("unsubstituted aryl") or substituted ("substituted aryl"). In some embodiments, the aryl group is an unsubstituted C 6-14 In certain embodiments, the aryl group is a substituted C 6-14 It is aryl.

[0063] "Substituted glycine compound" refers to a compound of formula II:

[0064] [ka]

[0065] (where R 1 , R 2 and R 3 and each independently represents hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl. In certain embodiments, in Formula II, R 1 , R 2 and R 3are not independently present. In certain embodiments, R 1 , R 2 and R 3 In certain embodiments, in Formula II, any one of R 1 , R 2 and R 3 All of these are present and the nitrogen is positively charged.

[0066] In certain embodiments, R 1 , R 2 and R 3 One of them is C 1-6 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, R 1 , R 2 and R 3 One of the C 1-3 In certain embodiments, R 1 , R 2 and R 3 In certain embodiments, one of R 1 , R 2 and R 3 One of the C 1-3 alkyl, and R 1 , R 2 and R 3 In certain embodiments, one of R 1 , R 2 and R 3 Two of them are C 1-6 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, R 1 , R 2 and R 3 Two of them are C 1-6 Alkyl (e.g., unsubstituted C 1-6 alkyl), and R 1 , R 2 and R 3 and the other is hydrogen. In certain embodiments, R 1 , R 2 and R 3 All three of them are C 1-6 Alkyl (e.g., unsubstituted C1-6 In certain embodiments, R 1 , R 2 and R 3 All three of these are unsubstituted C 1-3 It is alkyl.

[0067] In certain embodiments, R 1 is hydrogen and R 2 C 1-6 alkyl, and R 3 In certain embodiments, R 1 is hydrogen and R 2 is unsubstituted C 1-3 alkyl, and R 3 In certain embodiments, R 1 is hydrogen and R 2 is unsubstituted methyl, and R 3 In certain embodiments, R 1 C 1-6 alkyl, and R 2 is hydrogen, and R 3 In certain embodiments, R 1 is unsubstituted C 1-3 alkyl, and R 2 is hydrogen, and R 3 In certain embodiments, R 1 is unsubstituted methyl and R 2 is hydrogen, and R 3 In certain embodiments, R 1 does not exist and R 2 is hydrogen, and R 3 C 1-6 In certain embodiments, R 1 does not exist and R 2 is hydrogen, and R 3 is unsubstituted C 1-6 In certain embodiments, R 1 does not exist and R 2 is hydrogen, and R 3 is unsubstituted methyl.

[0068] In certain embodiments, the substituted glycine compound is

[0069] [ka]

[0070] (N-methylglycine, also known as sarcosine),

[0071] [ka]

[0072] (N-dimethylglycine), or

[0073] [ka]

[0074] (N-trimethylglycine) is.

[0075] The divalent bridging alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are designated with the suffix "-ene," to refer, for example, to alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene.

[0076] "Aralkyl" is a subset of alkyl and aryl and refers to an optionally substituted alkyl group that may be substituted with an optionally substituted aryl group. In certain embodiments, an aralkyl is an optionally substituted benzyl. In certain embodiments, an aralkyl is benzyl. In certain embodiments, an aralkyl is an optionally substituted phenethyl. In certain embodiments, an aralkyl is phenethyl.

[0077] "Heteroaryl" refers to a group of 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring systems (e.g., sharing 6 or 10 pi electrons in a cyclic arrangement) having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment is a carbon or nitrogen atom, valence permitting. Heteroaryl bicyclic ring systems can contain one or more heteroatoms on one or both rings. "Heteroaryl" includes ring systems in which a heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups, where the point of attachment is on the heteroaryl ring, and in such cases, the number of ring members continues to indicate the number of ring members in the heteroaryl ring system. "Heteroaryl" includes ring systems in which a heteroaryl ring, as defined above, is fused to one or more aryl groups, where the point of attachment is on either the aryl or heteroaryl ring, and in such cases the number of ring members continues to indicate the number of ring members in the fused (aryl / heteroaryl) ring system. Bicyclic heteroaryl groups are groups in which one ring does not contain heteroatoms (e.g., indolyl, quinolinyl, carbazolyl, etc.) and the point of attachment is on either ring, i.e., either the ring containing a heteroatom (e.g., 2-indolyl) or the ring without a heteroatom (e.g., 5-indolyl).

[0078] In some embodiments, heteroaryl groups are 5-10 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In some embodiments, heteroaryl groups are 5-8 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some embodiments, heteroaryl groups are 5-6 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl"). In some embodiments, 5-6 membered heteroaryls have 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some aspects, 5-6 membered heteroaryls have 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heteroaryl has one ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group independently may be optionally substituted, i.e., unsubstituted ("unsubstituted heteroaryl") or substituted ("substituted heteroaryl"). In some embodiments, the heteroaryl group is an unsubstituted 5- to 14-membered heteroaryl. In some embodiments, the heteroaryl group is a substituted 5- to 14-membered heteroaryl.

[0079] Typical 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Typical 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Typical 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Typical 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Typical 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Typical 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Typical 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Typical 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Typical 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Typical 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0080] "Unsaturated" or "partially unsaturated" refers to a group that contains at least one double or triple bond. "Partially unsaturated" ring systems are also intended to encompass rings with multiple sites of unsaturation, but are not intended to include aromatic groups (e.g., aryl or heteroaryl groups). Similarly, "saturated" refers to a group that does not contain double or triple bonds, i.e., a group that contains all single bonds.

[0081] Unless clearly indicated otherwise, atoms, moieties, or groups described herein may be unsubstituted or substituted, where valence allows. The term "optionally substituted" refers to substituted or unsubstituted.

[0082] Unless clearly indicated otherwise, groups may be optionally substituted. The term "optionally substituted" refers to substituted or unsubstituted. In some embodiments, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl, "substituted" or "unsubstituted" heteroaryl groups). In general, whether preceded by the term "optionally," the term "substituted" means that at least one hydrogen atom present on a group (e.g., a carbon or nitrogen atom) is replaced with an acceptable substituent, e.g., a substituent that, when substituted, results in a stable compound, e.g., a substituent that does not spontaneously undergo transformation, such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise specified, a "substituted" group has a substituent at one or more substitutable positions of the group, and when multiple positions in any given structure are substituted, the substituents can be the same or different at each position. The term "substituted" is intended to include substitution with all permissible substituents of organic compounds and includes all substituents described herein that result in the formation of stable compounds. The present disclosure contemplates any and all such combinations in order to arrive at stable compounds. For purposes of this disclosure, heteroatoms such as nitrogen can have hydrogen substituents and / or any suitable substituents described herein that satisfy the valence of the heteroatom and result in the formation of a stable moiety. In certain embodiments, the substituent is a carbon atom substituent. In certain embodiments, the substituent is an oxygen atom substituent. In certain embodiments, the substituent is a nitrogen atom substituent. In certain embodiments, the substituent is a sulfur atom substituent.

[0083] Typical carbon atom substituents include, but are not limited to, halogen,

[0084] [ka]

[0085] C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-10 aryl and 5- to 14-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; and X - is the counterion; Or two hydrogen atoms bonded to the same carbon atom are =O, =S, =NN(R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=0)2R aa , =NR bb or =NOR cc Replaced by radicals; R in each case aa independently, C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl and 5- to 14-membered heteroaryl, or two R aa groups linked to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group;

[0086] R in each case bb are independently hydrogen, -OH, -ORaa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2RR aa , -S02R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)(R aa )2, -P(=O)(OR cc )2, -P(=O)(N(R cc )2)2, C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl and 5- to 14-membered heteroaryl, or two R bb groups linked to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; where X - is the counterion; R in each case cc are independently hydrogen, C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl and 5- to 14-membered heteroaryl, or two Rcc groups linked to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group;

[0087] R in each case dd are independently -CN, -N02, -N3, -SO2H, -SO3H, -OH, -OR ee , -ON(R ff )2, -N(R ff )2, -N(R ff )3 + X - , -N(OR ee )R ff , -SH, -SR ee , -SSR ee , -C(=O)R ee , -C02H, -CO2R ee , -OC(=O)R ee , -OC02R ee , -C(=O)N(R ff )2, -OC(=O)N(R ff )2, -NR ff C(=O)R ee , -NR ff CO2R ee , -NR ff C(=O)N(R ff )2, -C(=NR ff ) OR ee , -OC(=NR ff )R ee , -OC(=NR ff ) OR ee , -C(=NR ff )N(R ff )2, -OC(=NR ff )N(R ff )2, -NR ff C(=NR ff )N(R ff )2, -NR ff S02R ee , -SO2N(R ff )2, -S02Ree , -S020R ee , -OS02R ee , -S(=O)R ee , -Si(R ee )3, -OSi(R ee )3-C(=S)N(R ff )2, -C(=O)SR ee , -C(=S)SR ee , -SC(=S)SR ee , -P(=O)(R ee )2, -P(=O)(R ee )2, -OP(=O)(R ee )2, -OP(=O)(OR ee )2,C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg or two R attached to the same atom dd The substituents taken together form =O or =S; where X - is the counterion; R in each case ee are independent, C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 aryl, 3- to 10-membered heterocyclyl, and 3- to 10-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg substituted with a group; and R in each case ff are independently hydrogen, C 1-6 Alkyl, C1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5- to 10-membered heteroaryl, or two R ff groups linked to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg substituted with a group; and

[0088] R in each case gg are independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 alkyl)2, -N(C 1-6 alkyl)2, -N(C 1-6 alkyl)3 + X - , -NH(C 1-6 -alkyl)2 + X - , -NH2(C 1-6 alkyl) + X - , -NH3 + X - , -N(OC 1-6 Alkyl)(C 1-6 alkyl), -N(OH)(C 1-6 alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 alkyl), -OC02(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)N(C1-6 alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 alkyl)2, -C(NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 alkyl), -SO2N(C 1-6 alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl)3, -OSi(C 1-6 alkyl)3, -C(=S)N(C 1-6 alkyl)2, -C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 alkyl), -SC(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)(OC 1-6 alkyl)2, -P(=O)(C 1-6 alkyl)2, -OP(=O)(C 1-6 alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl; or two R gg The substituents taken together form =O or =S; where X - is the counterion.

[0089] R in each case gg are independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 alkyl)2, -N(C 1-6 alkyl)2, -N(C 1-6 alkyl)3 + X - , -NH(C 1-6 -alkyl)2 + X - , -NH2(C 1-6 alkyl) + X - , -NH3 + X - , -N(OC 1-6 Alkyl)(C 1-6 alkyl), -N(OH)(C 1-6 alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 alkyl), -OC02(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)N(C 1-6 alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 alkyl), -NHCO2(C 1-6alkyl), -NHC(=O)N(C 1-6 alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 alkyl), -SO2N(C 1-6 alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl)3, -OSi(C 1-6 alkyl)3, -C(=S)N(C 1-6 alkyl)2, -C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)(OC 1-6 alkyl)2, -P(=O)(C 1-6 alkyl)2, -OP(=O)(C 1-6 alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl; or two R gg The substituents taken together form =O or =S; where X- is a counterion.

[0090] A "counterion" or "anionic counterion" is a negatively charged group that associates with a positively charged group to maintain electronic neutrality. Anionic counterions can be monovalent (i.e., contain one formal negative charge). Anionic counterions can also be multivalent (i.e., contain multiple formal negative charges), such as divalent or trivalent. Typical counterions include halide ions (e.g., F - , Cl - , Br - , I - ), NO3 - , ClO4 - , O.H. - , H2PO4 - , HSO4 - , sulfonate ions (e.g., methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, 10-camphorsulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1-sulfonic acid-5-sulfonic acid, ethane-1-sulfonic acid-2-sulfonic acid ions, etc.), carboxylate ions (e.g., acetic acid, propanoic acid, benzoic acid, glyceric acid, lactic acid, tartaric acid, glycolic acid, gluconic acid ions, etc.), BF4 - , PF4 - , PF6 - , AsF6 - , SbF6 - , B [3,5-(CF3)2C6H3]4] - , BPh4 - , Al(OC(CF3)3)4 - , and carborane anions (e.g., CB 11 H 12 - or (HCB 11 Me5Br6) - Typical counterions, which may be multivalent, include CO3 2- , HPO4 2- , PO4 3- , B4O7 2- , SO4 2- , S2O3 2-, carboxylate anions (e.g., tartaric acid, citric acid, fumaric acid, maleic acid, malic acid, malonic acid, gluconic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, salicylic acid, phthalic acid, aspartic acid, glutamic acid ions, etc.), and carboranes.

[0091] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).

[0092] "Acyl" is -C(=O)R aa , -CHO, -CO2R aa , -C(=O)N(R bb )2, -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb )2, -C(=O)NR bb SO2R aa , -C(=S)N(R bb )2, -C(=O)SR aa or -C(=S)SR aa where R aa and R bb is as previously defined.

[0093] Nitrogen atoms can be substituted or unsubstituted, where valence allows, and can include primary, secondary, tertiary, and quaternary nitrogen atoms. Typical nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -OR aa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR bb )R aa , -C(=NR cc ) OR aa , -C(=NRcc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)(OR cc )2, -P(=O)(R aa )2, -P(=O)(N(R cc )2)2, C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5- to 14-membered heteroaryl, or two R cc groups taken together form a 3- to 14-membered heterocyclyl or a 5- to 14-membered heteroaryl ring; wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group, and R aa , R bb , R cc and R dd is as defined above.

[0094] In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group). Nitrogen protecting groups include, but are not limited to, -OH, -OR aa , -N(R cc )2, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR cc )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(Rcc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , C 1-10 Alkyl (e.g., aralkyl), C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 and 5- to 14-membered heteroaryl groups, where each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group, and R aa , R bb , R cc and R dd is as defined above. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene & P.G.M. Wuts, 3rd Edition, John Wiley & Sons, 1999, which is incorporated herein by reference.

[0095] For example, a nitrogen protecting group such as an amide group (e.g., —C(═O)R aa) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N′-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivatives, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.

[0096] Nitrogen protecting groups such as carbamate groups (e.g., -C(=O)OR aa), including, but not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate ( Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methylethyl carbamate (Teoc ... t-butyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), biphenyl Nyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropyl allyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyl dithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenylcarbamate (Mtpc), 2,4-dimethylthiophenylcarbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropylcarbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chloro Monylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzylthiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2, 2-Dimethoxyacylvinylcarbamate, o-(N,N-dimethylcarboxamido)benzylcarbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propylcarbamate, 1,1-dimethylpropynylcarbamate, di(2-pyridyl)methylcarbamate, 2-furanylmethylcarbamate, 2-iodoethylcarbamate, isoborinylcarbamate, isobutylcarbamate, isonicotinylcarbamate, p-(p′-methoxyphenylazo)benzylcarbamate, 1-methylcyclobutylcarbamate, 1 -methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.

[0097] Nitrogen protecting groups such as sulfonamide groups (e.g., -S(=O)2-R aa ), including, but not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

[0098] Other nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivatives, N'-p-toluenesulfonylaminoacyl derivatives, N'-phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldiphenylamine ... Silylazacyclopentane adducts (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-ones, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-ones, 1-substituted 3,5-dinitro-4-pyridones, N-methylamines, N-allylamines, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrroline-3-)- yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N′-oxide, N-1,1-dimethyl Thiomethyleneamine, N-benzylideneamine, Np-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine, Np-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivatives, N-diphenylboronic acid derivatives, N-[phenyl(pentaacychromium or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidate, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridine sulfenamide (Npys).

[0099] Typical oxygen atom substituents include, but are not limited to, -R aa , -C(=O)SR aa , -C(=O)R aa , -CO2R aa , -C(=O)N(R bb )2, -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb )2, -S(=O)R aa , -SO2R aa , -Si(R aa )3, -P(R cc )2, -P(R cc )3 + X - , -P(OR cc )2, -P(OR cc )3 + X - , -P(=O)(R aa )2, -P(=O)(OR cc )2 and -P(=O)(N(R bb)2)2 is mentioned, where X - , R aa , R bb and R cc is as previously defined.

[0100] In certain embodiments, the oxygen atom substituent present on the oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group). Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene & PGM Wuts, 3rd Edition, John Wiley & Sons, 1999 (which is incorporated herein by reference). Exemplary oxygen protecting groups include, but are not limited to, methyl, t-butyloxycarbonyl (BOC or Boc), methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (M THP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxytetrahydrothiopyranyl thoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-Dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, diphenylmethyl, p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4, 4',4"-Tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4"-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodisulfuran-2-yl, benzisothiazolyl S,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylethylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), benzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzyl formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyl dithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-Trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Psec), 2-(triphenylphosphonio)ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate Carbonate, alkyl aryl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-diisopropyl methyl ... o-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate nitrate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxyacyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N′,N′-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).

[0101] The term "pharmaceutically acceptable salt" refers to a salt that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans or lower animals without undue toxicity, irritation, allergic response, or the like, and that is commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, pp. 1-19, which is incorporated herein by reference.

[0102] Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by other methods known in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, and 2-hydroxy-ethanesulfonate. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N-methyl-N ... + (C 1-4Alkyl)4 - Typical alkali or alkaline earth salts include sodium, lithium, potassium, calcium, magnesium salts, etc. Further pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium salts, quaternary ammonium salts, and amine cation salts formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.

[0103] The term "solvate" refers to a form of a compound that is associated with a solvent, usually by solvolysis. This physical association may involve hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), diethyl ether, and the like. The compounds described herein may be prepared, for example, in crystalline form and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric and non-stoichiometric solvates. In certain cases, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, and methanolates.

[0104] The term "crystal" or "crystalline form" refers to a solid form that exhibits substantial three-dimensional order. In certain embodiments, a solid crystalline form is a solid form that is substantially non-amorphous. In certain embodiments, the X-ray powder diffraction (XRPD) pattern of the crystalline form comprises one or more sharply defined peaks.

[0105] The terms "amorphous" or "amorphous form" refer to a form of a solid ("solid form") that substantially lacks three-dimensional order. In certain embodiments, a solid amorphous form is a solid form that is substantially non-crystalline. In certain embodiments, the X-ray powder diffraction (XRPD) pattern of the amorphous form comprises a broad scattering band, e.g., with a peak at 2θ between 20° and 70° (inclusive), using CuKα radiation. In certain embodiments, the XRPD pattern of the amorphous form further comprises one or more peaks attributable to crystalline structure. In certain embodiments, the maximum intensity of any one of one or more peaks attributable to crystalline structure observed between 2θ between 20° and 70° (inclusive) is 300 times or less, 100 times or less, 30 times or less, 10 times or less, or 3 times or less than the maximum intensity of the broad scattering band. In certain embodiments, the XRPD pattern of the amorphous form does not comprise any peaks attributable to crystalline structure.

[0106] The term "cocrystal" refers to a crystal structure comprising at least two different components (e.g., N-methylglycine and a coformer), where each of the components is independently an atom, ion, or molecule. Unlike salts, which are ionic or ionically bonded crystalline compounds when in crystalline form, cocrystals comprise two or more different molecules within the same crystal lattice associated by nonionic and noncovalent bonds. That is, in certain embodiments, each component in a cocrystal is in a neutral state that does not undergo proton transfer, in contrast to a crystalline salt compound. In certain embodiments, none of the components is a solvent. In certain embodiments, at least one of the components is a solvent. A cocrystal of N-methylglycine and a coformer is distinct from a salt formed from N-methylglycine and a coformer. In the case of a salt, N-methylglycine is complexed with the coformer in such a way that proton transfer (e.g., complete proton transfer) from the coformer to N-methylglycine occurs at room temperature. However, in the case of cocrystals, N-methylglycine is complexed with the coformer in such a way that proton transfer from the coformer to the N-methylglycine does not readily occur at room temperature. In some embodiments, no proton transfer from the coformer to the N-methylglycine occurs in the cocrystal. In some embodiments, partial proton transfer from the coformer to the N-methylglycine occurs in the cocrystal. Cocrystals may be useful for improving the properties of N-methylglycine (e.g., solubility, stability, ease of formulation, or bioavailability).

[0107] The term "tautomer" or "tautomerism" refers to two or more interconvertible compounds resulting from the geometrical shift of at least one hydrogen atom and at least one change in valence (e.g., from a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. Tautomerization (i.e., the reaction that provides a tautomeric pair) can be catalyzed by acid or base. Exemplary tautomerizations include keto-enol, amide-imide, lactam-lactim, enamine-imine, enol-keto, and enamine-(another enamine) tautomerizations.

[0108] It should also be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers."

[0109] Stereoisomers that are not mirror images of one another are called "diastereomers," while those that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, when the asymmetric center is attached to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and are described by the R- and S-ordering rules of Cahn and Prelog, or by how the molecule rotates the plane of polarized light and is designated as dextrorotatory or levorotatory (i.e., (+) or (-) isomer, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0110] The term "polymorph" refers to a crystalline form of a compound (or its salt, hydrate, or solvate) in a particular crystalline close-packed arrangement. All polymorphs have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystalline shapes, optical and electrical properties, stability, and solubility. Recrystallization solvents, crystallization rates, storage temperatures, and other factors can cause one crystalline form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.

[0111] The term "prodrug" refers to a compound having a cleavable group that becomes a pharmaceutically active compound of the present invention in vivo upon solvolysis or under physiological conditions. Examples include, but are not limited to, choline ester derivatives, N-alkylmorpholine esters, and the like. Other derivatives of the compounds described herein are active in both their acid and acid-derivative forms, but often offer advantages of solubility, tissue compatibility, or delayed release in the acid-sensitive form (see Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam, 1985). Prodrugs include acid derivatives well known to those skilled in the art, such as esters prepared by reacting the parent acid with an appropriate alcohol, or amides prepared by reacting the parent acid with a substituted or unsubstituted amine, or acid anhydrides or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds described herein are specific prodrugs. In some cases, it may be desirable to prepare double ester prodrugs, such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. The compounds described herein may be used in combination with C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C7-C8 alkyl esters. 12 Substituted aryl and C7-C 12 Aryl alkyl esters may be preferred in some cases.

[0112] The terms "inhibit," "inhibit," "inhibiting," or "inhibitor" refer to the ability of a cocrystal to reduce, slow, stop, or prevent the activity of a particular biological process in a cell relative to an excipient.

[0113] When a co-crystal, pharmaceutical composition, method, use, or kit is referred to as "selectively," "specifically," or "competitively" binding a first protein, the co-crystal binds the first protein with a higher binding affinity (e.g., about 2-fold or more, about 5-fold or more, about 10-fold or more, about 30-fold or more, about 100-fold or more, about 1,000-fold or more, or about 10,000-fold or more) than it binds a second protein (i.e., a protein that is different from the first protein). When a co-crystal is referred to as "selectively," "specifically," or "competitively" modulating the activity of a protein, the co-crystal modulates the activity of the protein to a greater extent (e.g., about 2-fold or more, about 5-fold or more, about 10-fold or more, about 30-fold or more, about 100-fold or more, about 1,000-fold or more, or about 10,000-fold or more) than the activity of at least one protein that is different from the first protein.

[0114] The term "abnormal activity" refers to an activity that deviates from the normal activity. The term "increased activity" refers to an activity that is higher than the normal activity.

[0115] The terms "composition" and "formulation" are used interchangeably.

[0116] A "subject" to which administration is contemplated refers to a human (i.e., male or female of any age, e.g., a pediatric subject (e.g., an infant, child, or adolescent) or an adult subject (e.g., a young adult, middle-aged adult, or elderly)) or a non-human animal. A "patient" refers to a human subject in need of treatment for a disease.

[0117] The terms "administer," "administering," or "administration" refer to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing into a subject a cocrystal described herein or a composition thereof.

[0118] The terms "treatment," "treating," and "treating" refer to reversing, alleviating, delaying the onset, or inhibiting the progression of a disease described herein. In some embodiments, treatment can be administered after one or more signs or symptoms of the disease have occurred or have been observed. In other embodiments, treatment can be administered in the absence of signs or symptoms of the disease. For example, treatment can be administered to a susceptible subject (e.g., in light of previous symptoms and / or exposure to a pathogen) prior to the onset of symptoms to delay or prevent the onset of the disease. Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.

[0119] The terms "condition," "disease," and "disorder" are used interchangeably.

[0120] An "effective amount" of a cocrystal described herein refers to an amount sufficient to elicit a desired biological response, i.e., sufficient to treat a disease. As will be understood by one of skill in the art, the effective amount of a cocrystal described herein can vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the cocrystal, the condition to be treated, the mode of administration, and the age and health of the subject. In some embodiments, the effective amount is a therapeutically effective amount. In some embodiments, the effective amount is a prophylactically effective amount. In some embodiments, the effective amount is the amount of a cocrystal described herein in a single administration. In some embodiments, the effective amount is the total amount of a cocrystal described herein in multiple administrations.

[0121] A "therapeutically effective amount" of a cocrystal described herein is an amount sufficient to provide a therapeutic benefit in treating a disease or to delay or minimize one or more symptoms associated with the disease. A therapeutically effective amount of a cocrystal means an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in treating a disease. The term "therapeutically effective amount" can encompass an amount that improves overall treatment, reduces or avoids symptoms, signs, or causes of a disease, and / or enhances the therapeutic efficacy of another therapeutic agent.

[0122] A "prophylactically effective amount" of a cocrystal described herein is an amount sufficient to prevent or prevent the recurrence of a disease, or one or more symptoms associated with the disease. A prophylactically effective amount of a cocrystal means an amount of a therapeutic agent, alone or in combination with other therapies, that provides a prophylactic benefit in the prevention of a disease. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

[0123] The term "neurological disorder" refers to any disorder of the nervous system, including disorders involving the central nervous system (brain, brainstem, spinal cord, and cerebellum), peripheral nervous system (including cranial nerves), and autonomic nervous system (the portion located between the central and peripheral nervous systems). Neurodegenerative disorders refer to a class of neurological disorders characterized by neuronal loss, including, but not limited to, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, tauopathies (including frontotemporal dementia), multiple system atrophy, and Huntington's disease. Examples of neurological disorders include, but are not limited to, headaches, stupor and coma, dementia, seizures, sleep disorders, trauma, infections, tumors, neuro-ophthalmological disorders, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of the peripheral nerves, muscles, and neuromuscular junction. Addiction and psychiatric disorders, including depression, suicidal ideation and / or behavior, and bipolar disorder and schizophrenia are also included in the definition of neurological disorder or CNS disorder. Further examples of neurological disorders include acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers disease; alternating hemiplegia; Alzheimer's disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cyst; arachnoiditis; Arnold-Chiari malformation; arteriovenous malformation; Asperger's syndrome; ataxia-telangiectasia; attention-deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; chronic pain; Batten disease; Behçet's disease; Bell's palsy; benign essential blepharospasm; benign focal muscular atrophy; benign intracranial hypertension; Binswanger's disease; blepharospasm; Bloch-Sulzberger syndrome; brachial plexus injury; brain abscess; brain injury; brain tumor (including glioblastoma multiforme); spinal cord tumor; Brown-Séquard syndrome; Canavan disease; carpal tunnel syndrome (CTS) ); Burning fever; Central pain syndrome; Central pontine myelinopathy; Head injury; Cerebral aneurysm; Cerebral arteriosclerosis; Cerebral atrophy; Cerebral gigantism; Cerebral palsy; Charcot-Marie-Tooth disease; Chemotherapy-induced neuropathy and neuropathic pain; Chiari malformation; Chorea; Chronic inflammatory demyelinating polyneuropathy (CIDP); Chronic pain; Chronic focal pain syndrome; Coffin-Lowry syndrome; Coma including persistent vegetative state; Congenital facial diplegia; Corticobasal degeneration; Cranial arteritis; Craniosynostosis; Creutzfeldt-Jakob disease; Cumulative trauma disorder;Cushing's syndrome; Cytomegalovirus inclusion body disease (CIBD); Cytomegalovirus infection; Nystagmus-leg shaking syndrome; Dandy-Walker syndrome; Dawson's disease; De Morcher syndrome; Dejerine-Klumpke palsy; Dementia; Dermatomyositis; Diabetic neuropathy; Diffuse sclerosis; Autonomic neuropathy; Dysgraphia; Dyslexia; Dystonia; Early infantile epileptic encephalopathy; Empty-Sella syndrome; Encephalitis; Encephalopathy; Trigeminal region angiomatosis; Epilepsy; Erb's palsy; Essential tremor; Fabry's disease; Fahr's syndrome; Syncope; Familial spastic paraparesis; Febrile seizures; Fisher's syndrome; Friedreich's ataxia; Frontotemporal dementia and other "tauopathies"; Go Sher disease; Gerstmann's syndrome; giant cell arteritis; giant cell inclusion body disease; globoid cell leukodystrophy; Guillain-Barré syndrome; HTLV-1-associated myelopathy; Hallervorden-Spatz disease; head trauma; headache; hemifacial spasm; hereditary spastic paraplegia; hereditary polyneuropathies; varicella zoster oticus; herpes zoster; Hirayama syndrome; HIV-associated dementia and neuropathy (see also Neurological Manifestations of AIDS); holoprosencephaly; Huntington's disease and other polyglutamine repeat diseases; hydranencephaly; hydrocephalus; hyperadrenocorticism; hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile phytanic acid storage disease; childhood Refsum's disease; infantile spasms; inflammatory myopathy; intracranial cysts; increased intracranial pressure; Joubert syndrome; Kearns-Sayre syndrome; Kennedy disease; Kinsbone syndrome; Klippel-Feil syndrome; Krabbe disease; Kugelberg-Welander disease; Kuru; Lafora disease; Lambert-Eaton syndrome; Landau-Kleffner syndrome; Transverse myelo-myelo-(Wallenberg) syndrome; Learning disability; Leigh disease; Lennox-Gastaut syndrome; Lesch-Nyhan syndrome; Leukodystrophy; Dementia with Lewy bodies; Lissencephaly; Locked-in syndrome; Lou Gehrig's disease (also known as motor neuron disease or myelopathy) amyotrophic lateral sclerosis); lumbar disc disease; Lyme disease - neurological sequelae; Machado-Joseph disease; cerebrospinal myelopathy; megaloencephaly; Melkerson-Rosenthal syndrome; Meniere's disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; migraine; Miller-Fisher syndrome; minor stroke; mitochondrial myopathy; Moebius syndrome; single limb muscular atrophy; motor neuron disease; moyamoya disease; mucopolysaccharidosis; multiinfarct dementia; multifocal motor neuropathy;Multiple sclerosis and other demyelinating diseases; multiple system atrophy with orthostatic hypotension; muscular dystrophies; myasthenia gravis; diffuse sclerosis with myelin destructive disorder; infantile myoclonic encephalopathy; myoclonus; myopathy; congenital myotonia; narcolepsy; neurofibromatosis; neuroleptic malignant syndrome; neurological manifestations of AIDS; neurological sequelae of lupus; neuromyitis; neuronal ceroid lipofuscinosis; neuronal migration disorders; Niemann-Pick disease; O'Sullivan-McLeod syndrome; occipital neuralgia ; Subclinical spinal dysraphism; Ohtahara syndrome; Olivopontocerebellar atrophy; Opsoclonus-myoclonus; Optic neuritis; Orthostatic hypotension; Overuse syndrome; Paresthesia; Parkinson's disease; Congenital myotonic spasms; Paraneoplastic disorders; Paroxysmal attacks; Parry-Romberg syndrome; Pelizaeus-Merzbacher disease; Periodic paralysis; Peripheral neuropathy; Painful neuropathy and neuropathic pain; Persistent vegetative state; Pervasive developmental disorder; Photophobic sneeze reflex; Phytanic acid storage disease; Pick's disease; Pinched nerve; Pituitary tumors; Polymyositis; Porencephaly; Post-polio syndrome; Postherpetic neuralgia (PHN); Post-infectious encephalomyelitis; Orthostatic hypotension; Prader-Willi syndrome; Primary lateral sclerosis; Prion disease; Progressive; Hemifacial atrophy; Progressive multifocal leukoencephalopathy; Progressive sclerosing poliodystrophy; Progressive supranuclear palsy; Pseudotumor cerebri; Ramsay-Hunt syndrome (Types I and II); Rasmussen encephalitis; Reflex sympathetic dystrophy syndrome; Refsum's disease; Repetitive movement disorder; Repetitive stress injury; Restless legs syndrome; Retrovirus-associated myelopathy; Rett syndrome; Reye's syndrome; St. Vitus's chorea; Sandhoff disease; Schilder's disease; Schizencephaly; Septo-optic dysplasia; Shaken baby syndrome; Shingles; Shy-Drager syndrome; Sjogren's syndrome; Sleep apnea; Soto syndrome; Spasticity; Spina bifida; Spinal cord injury; Spinal cord tumor; Spinal muscular atrophy; Stiff-person syndrome; Stroke; Sturge-Weber syndrome; Subacute sclerosing panencephalitis; Subarachnoid hemorrhage; Subcortical arteriosclerotic encephalopathy; Sydenham's chorea; Syncope; syringomyelia; tardive dyskinesia; Tay-Sachs disease; temporal arteritis; tethered cord syndrome; Thomsen's disease; thoracic outlet syndrome; painful tics; Todd's palsy; Tourette's syndrome; transient ischemic attack; transmissible spongiform encephalopathy; transverse myelitis; traumatic brain injury; tremor; trigeminal neuralgia; tropical spastic paraplegia; tuberous sclerosis;Vascular dementia (multi-infarct dementia); vasculitis involving the temporal arteries; von Hippel-Lindau disease (VHL); Wallenberg syndrome; Werdnig-Hoffmann disease; West syndrome; whiplash syndrome; Williams syndrome; Wilson disease; and Zellweger syndrome.

[0124] The term "mental disorder" means a mental illness and includes those diseases and disorders listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th and 5th editions (DSM-IV, DSM-V) (1994, 2015) published by the American Psychiatric Association (Washington, DC). Mental disorders include, but are not limited to, anxiety disorders (e.g., acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, and specific phobias), childhood disorders (e.g., attention-deficit / hyperactivity disorder, conduct disorder, and oppositional defiant disorder), eating disorders (e.g., anorexia nervosa and bulimia nervosa), mood disorders (e.g., depression, bipolar I disorder and bipolar II disorder, cyclothymic disorder, dysthymic disorder, and major depressive disorder), suicidal thoughts and / or behaviors, personality disorders (e.g., antisocial personality disorder, avoidant personality disorder, borderline personality disorder, dependent personality disorder, histrionics, and the like). personality disorder, narcissistic personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder, schizophrenic personality disorder, and schizophrenic personality disorder), psychoses (e.g., brief psychosis, delusional disorder, schizoaffective disorder, schizophreniform disorder, schizophrenia, and shared psychosis), substance-related disorders (e.g., alcohol dependence or addiction, amphetamine dependence or addiction, cannabis dependence or addiction, cocaine dependence or addiction, hallucinogen dependence or addiction, inhalant dependence or addiction, nicotine dependence or addiction, stimulant dependence or addiction, phencyclidine dependence or addiction, and sedative dependence or addiction), and Tourette's syndrome.

[0125] The term "neuropsychiatric disorder," which includes either neurological or psychiatric disorders or CNS disorders, refers to disorders that involve psychiatric symptoms or syndromes caused by organic brain damage. Key features of neuropsychiatric disorders include the occurrence of various psychiatric symptoms, cognitive impairment, and the possibility of neurological symptoms or early brain development symptoms.

[0126] The terms "health food" and "health foodstuffs" refer to any type of liquid and solid / semi-solid material used to improve basic behavioral function, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and / or cognitive function, weight, etc., or to facilitate the treatment of any of the target diseases described herein. The term "nutraceutical composition" refers to a composition that contains ingredients from food sources and confers additional health benefits beyond the basic nutritional value found in foods.

[0127] The term "medical food" generally refers to a food formulated to be consumed or administered enterally, including foods used under medical supervision for the specific dietary management of a target disease, such as those described herein. A "medical food" composition refers to a composition (as opposed to a naturally occurring foodstuff used in its natural state) that is specially formulated and processed for a patient in need of treatment (e.g., a human patient suffering from a disease or requiring the use of a product as the primary active agent to alleviate a disease or condition with a special dietary regimen). [Brief explanation of the drawings]

[0128] [Figure 1] FIG. 1 shows the H-NMR analysis of N-methylglycine:D-tartaric acid (1:1 co-crystal) from Example 1.

[0129] [Figure 2]FIG. 2 shows the X-ray powder diffraction (XRPD) of N-methylglycine:D-tartaric acid (1:1 co-crystal) from Example 1, with the following peaks at 2θ angles (°): 11.0, 14.2, 18.2, 19.4, 19.9, 21.6, 22.0, 22.5, 24.0, 24.8, 26.2, 26.7, 27.0, 28.3, 28.6, 30.5, 30.9, 31.6, 32.4, 33.3, 34.1, 35.3, 35.9, 36.4, 36.8, 37.3, 38.6, 38.9, 39.4, 40.0, 40.3, 41.5, 41.8, 41.9, 42.1, 42.2, 42.3, 42.5, 42.6, 42.8, 43.0, 43.3, 43.5, 43.8, 44.0, 44.1.

[0130] [Figure 3] FIG. 3 shows the thermogravimetric analysis (TGA) of N-methylglycine:D-tartaric acid (1:1 co-crystal) from Example 1.

[0131] [Figure 4] FIG. 4 shows differential scanning calorimetry (DSC) data for N-methylglycine:D-tartaric acid (1:1 co-crystal) from Example 1.

[0132] [Figure 5] FIG. 5 shows the H-NMR of N-methylglycine:L-tartaric acid (1:1 co-crystal) from Example 2.

[0133] [Figure 6] FIG. 6 shows the X-ray powder diffraction (XRPD) of N-methylglycine:L-tartaric acid (1:1 co-crystal) from Example 2, with the following peaks in 2θ angles (°): 11.0, 14.2, 18.2, 19.4, 20.0, 21.7, 22.0, 22.5, 24.1, 24.8, 26.2, 26.7, 27.0, 28.3, 28.6, 28.8, 30.5, 30.9, 31.6, 32.5, 33.1, 33.3, 34.1, 35.3, 35.9, 36.4, 36.8, 37.3, 38.6, 38.8, 39.3, 40.0, 40.3, 41.5, 41.6, 41.9, 42.5, 43.0, 43.4, and 43.9.

[0134] [Figure 7] FIG. 7 shows the TGA of N-methylglycine:L-tartaric acid (1:1 co-crystal) from Example 2.

[0135] [Figure 8] FIG. 8 shows the DSC of N-methylglycine:L-tartaric acid (1:1 co-crystal) from Example 2.

[0136] [Figure 9] FIG. 9 shows the H-NMR of N-methylglycine:DL-tartaric acid (1:1 co-crystal) from Example 3.

[0137] [Figure 10] FIG. 10 shows the XRPD of N-methylglycine:DL-tartaric acid (1:1 co-crystal) from Example 3, with the following peaks in 2θ angles (°): 10.9, 14.2, 18.2, 19.4, 19.9, 21.7, 22.0, 22.5, 24.0, 24.8, 26.2, 26.6, 27.0, 28.3, 28.5, 28.8, 30.5, 30.9, 31.5, 32.4, 33.1, 33.3, 34.1, 35.2, 35.9, 36.4, 36.8, 37.3, 38.6, 38.8, 39.3, 39.9 , 40.0, 40.2, 41.5, 41.6, 41.8, 42.3, 42.5, 42.9, 43.0, 43.4, and 43.8.

[0138] [Figure 11] FIG. 11 shows the TGA of N-methylglycine:DL-tartaric acid (1:1 co-crystal) from Example 3.

[0139] [Figure 12] FIG. 12 shows the DSC of N-methylglycine:DL-tartaric acid (1:1 co-crystal) from Example 3.

[0140] [Figure 13] FIG. 13 shows the H-NMR of N-methylglycine:L-tartaric acid (2:1 co-crystal) from Example 4.

[0141] [Figure 14] FIG. 14 shows the XRPD of N-methylglycine:L-tartaric acid (2:1 co-crystal) from Example 4, with the following peaks in 2θ angles (°): 8.1, 10.0, 11.9, 12.7, 13.3, 13.7, 15.5, 15.9, 16.3, 16.7, 17.8, 18.9, 19.8, 20.1, 21.2, 22.1, 24.0, 24.7, 25.0, 25.9, 26.2, 27.6, 28.0, 28.6, 29.4, 29.9, 30.1, 30.2, 30.6, 31.3, 31.8, 31.9, 32.2, 32.6, 33.4, 33.8, 34.7, 35.8, 36.4, 37.0, 38.8, 39.2, 39.7, 39.9, 40.2, 41.1, 41.5, 41.8, 41.9, 42.0, 42.8, 42.9, 43.1, 44.0, 44.1, and 44.5.

[0142] [Figure 15] FIG. 15 shows the TGA of N-methylglycine:L-tartaric acid (2:1 co-crystal) from Example 4.

[0143] [Figure 16] FIG. 16 shows the DSC of N-methylglycine:L-tartaric acid (2:1 co-crystal) from Example 4.

[0144] [Figure 17] FIG. 17 shows the hygroscopicity of N-methylglycine:L-tartaric acid (1:1 co-crystal, left side) and N-methylglycine:L-tartaric acid (2:1 co-crystal, right side) from Example 5.

[0145] [Figure 18] FIG. 18 shows the hygroscopicity of N-methylglycine:L-tartaric acid (1:1 co-crystal) and N-methylglycine:L-tartaric acid (2:1 co-crystal) from Example 6.

[0146] [Figure 19]FIG. 19 shows the hygroscopicity of N-methylglycine, L-tartaric acid, and the N-methylglycine:L-tartaric acid (1:1 co-crystal) from Example 8.

[0147] [Figure 20] FIG. 20 shows the XRPD of N-methylglycine:fumaric acid (1:1 co-crystal) from Example 11, with the following peaks in 2θ angles (°): 9.81, 11.10, 12.44, 13.99, 15.05, 17.63, 18.65, 19.20, 20.05, 20.80, 20.94, 22.41, 22.60, 23.51, 23.84, 24.61, 25.01, 26.95, 27.25, 28.07, 28.66, 29.23, 29.75, 30.05, 31.85, 33.23, 33.42, 35.49, 36.12, 37.94, 38.15, and 38.58.

[0148] [Figure 21] FIG. 21 shows the XRPD of N-methylglycine:fumaric acid (2:1 co-crystal) from Example 11, with the following peaks in 2θ angles (°): 7.66, 9, 89, 12.06, 12.78, 14.00, 15.52, 16.40, 16.58, 17.14, 17.49, 18.42, 19.74, 20.12, 20.75, 22.22, 22.46, 22.93, 23.16, 23.93, 24.29, 24.52, 24.66, 25.32, 25.66, 26.18, 26.98, 27.86, 29.00, 31.06, 31.41, 31.62, 32.96 , 33.28, 33.46, 34.45, 34.70, 35.55, and 37.01.

[0149] [Figure 22]FIG. 22 shows the XRPD of N-methylglycine:fumaric acid (3:1 co-crystal) from Example 11, with the following peaks in 2θ angles (°): 12.03, 12.70, 14.12, 15.50, 16.42, 16.52, 17.21, 18.29, 20.15, 22.16, 22.35, 22.88, 23.02, 23.17, 24.11, 24.43, 25.66, 26.22, 27.09, 27.87, 28.30, 28.53, 29.00, 30, 41, 31.24, 31.38, 31.65, 33.13, 33.42, 34.33, 34.68, 35.55 , 36.37, 36.92, and 39.79.

[0150] [Figure 23] FIG. 23 shows the XRPD of N-methylglycine:fumaric acid (6:1 co-crystal) from Example 11, with the following peaks in 2θ angles (°): 9.66, 12.30, 15.00, 16.55, 17.07, 18.51, 19.98, 20.39, 22.43, 22.79, 23.43, 24.63, 24.99, 25.84, 26.06, 26.92, 27.11, 27.90, 28.17, 29.05, 29.40, 30.19, 30.49, 32.81, 33.29, 33.34, 34.52, 34.76, 34.97, 35.20, 35.57, 35.99, 37.75 , and 38.36.

[0151] [Figure 24] FIG. 24 shows that N-methylglycine:L-tartaric acid (1:1) cocrystal (N-MG / L-TA 1:1) reduces MK-801-induced hyperlocomotion in a dose-dependent manner as observed in a mouse model.

[0152] [Figure 25] FIG. 25 shows the effect of N-MG / L-TA cocrystals in restoring prepulse inhibition disrupted by MK-801.

[0153] [Figure 26]FIG. 26 shows the effect of N-methylglycine:L-tartaric acid co-crystals (2:1 and 1:1) on the rate of recovery of locomotor activity in MK-801-treated mice.

[0154] [Figure 27] FIG. 27 shows the effect of various doses of N-MG / L-TA 2:1 cocrystal on locomotor activity in MK-801-treated mice.

[0155] [Figure 28] FIG. 28 shows the effect of various doses of N-MG / L-TA 2:1 cocrystal on the rate of recovery of locomotor activity in MK-801-treated mice.

[0156] [Figure 29] FIG. 29 shows the effect of N-MG / L-TA 2:1 cocrystal in restoring prepulse inhibition disrupted by MK-801.

[0157] [Figure 30] FIG. 30 shows the effect of N-MG / L-TA 2:1 cocrystal on spatial memory retrieval in MK-801-treated mice. DETAILED DESCRIPTION OF THE INVENTION

[0158] The present disclosure provides cocrystals of a substituted glycine compound, such as N-methylglycine, N-dimethylglycine, or N-trimethylglycine, with a coformer that is a compound of Formula (I) as described herein. Such cocrystals are expected to have advantageous physical, chemical, physiological, and / or therapeutic characteristics compared to the substituted glycine compound in a non-cocrystal form or a different cocrystal form. For example, substituted glycine cocrystals are expected to exhibit advantageous properties, including improved hygroscopicity, solubility, dissolution rate, physical stability, chemical stability, bioavailability, processability, and superior pharmacological or therapeutic properties. Such cocrystals are useful for treating and / or reducing the risk of various diseases and disorders, such as neuropsychiatric disorders, in subjects. Accordingly, methods, compositions, kits, and methods of use for preparing the cocrystals described herein for treating and / or reducing the risk of any of the target diseases described herein are also provided.

[0159] Cocrystals of substituted glycine compounds and coformers One aspect of the present invention relates to co-crystals of substituted glycine compounds described herein and coformers, as well as hydrates, polymorphs, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof, which are useful for treating and / or reducing the risk of neuropsychiatric disorders in a subject.

[0160] In certain embodiments, the co-crystals described herein are co-crystals of a substituted glycine compound, such as N-methylglycine, N-dimethylglycine, or N-trimethylglycine, with a co-former, wherein the co-former is a compound of formula (I):

[0161] [ka]

[0162] (Wherein A, B, W, X, Y, Z and

[0163] [ka]

[0164] is as previously defined), or a solvate, hydrate, polymorph, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof.

[0165] In formula (I), in some embodiments, A can be OH. In some embodiments, A can be H. In formula (I), in some embodiments, B can be OH. In some embodiments, B can be H.

[0166] In formula (I), in some embodiments, W can be O. In some embodiments, W can be NH. In formula (I), in certain embodiments, X can be H. In some embodiments, X is absent.

[0167] In some embodiments, Y can be C=O. In some embodiments, Y is -CR1R2, where R1 and R2 are independently H, alkyl, alkenyl, or alkynyl. In some embodiments, Y can be -CH2. In some embodiments, Y can be -CH(C 1-6 In some embodiments, Y can be -CH(unsubstituted C 1-3 In some embodiments, Y can be -C(C alkyl). 1-6 In some embodiments, Y can be -C(unsubstituted C alkyl) (e.g., -CMe or -CEt). 1-3 alkyl)2.

[0168] In some embodiments, Z can be OH. In some embodiments, Z can be -CH(OH)R3, where the C atom of -CH(OH)R3 is in the (R) configuration, and R3 can be H or alkyl (e.g., optionally substituted with -OH groups). In some embodiments, Z can be -CH(OH)R3, where the C atom of -CH(OH)R3 is in the (R) configuration, and R3 can be H or alkyl (e.g., optionally substituted with -OH groups). 1-6 In some embodiments, Z is C substituted with -OH. 1-3 In some embodiments, Z can be -CH(OH)H. In some embodiments, Z can be -CH(OH)(unsubstituted C 1-3 In some embodiments, Z can be —CH(OH)Me. In some embodiments, Z can be —CH(OH)Et. In some embodiments,

[0169] [ka]

[0170] is C2-C1, where C2 and C1 are linked by a single bond.

[0171] [ka]

[0172] In some embodiments, C2=C1, where C2 and C1 are connected by a double bond.

[0173] [ka]

[0174] In this case, C1 and C2 are both SP 3 or SP 2 It is a coordinated carbon.

[0175] In some embodiments, the substituted glycine compound and the coformer of Formula (I) can be present in the cocrystal in a molecular ratio ranging from 1:0.5 to 1:1.5. In some embodiments, the substituted glycine compound and the coformer of Formula (I) can be present in the cocrystal in a molecular ratio ranging from 1:0.6 to 1:1.4. In some embodiments, the substituted glycine compound and the coformer of Formula (I) can be present in the cocrystal in a molecular ratio ranging from 1:0.7 to 1:1.3. In some embodiments, the substituted glycine compound and the coformer of Formula (I) can be present in the cocrystal in a molecular ratio ranging from 1:1 to 1:1.5, for example, from 1:1 to 1:1.3. In some embodiments, the substituted glycine compound and the coformer of Formula (I) can be present in the cocrystal in a molecular ratio ranging from 1:1 to 1:1.2. In some embodiments, the substituted glycine compound and the coformer of Formula (I) can be present in the cocrystal in a molar ratio ranging from 1:1 to 1:1.1. In some embodiments, the substituted glycine compound and the coformer of Formula (I) can be present in the cocrystal in a molar ratio ranging from 6:1 to 1:1, e.g., 6:1, 5:1, 4:1, 3:1, 2:1, or 1:1.

[0176] In some embodiments, the coformer compound of formula (I) has formula (IA):

[0177] [ka]

[0178] where

[0179] [ka]

[0180] and Z is as defined above. In some embodiments, the coformer compound has the formula:

[0181] [ka]

[0182] (tartaric acid). In some embodiments, the coformer compound is L-tartaric acid. In some embodiments, the coformer compound is D-tartaric acid. In some embodiments, the coformer compound is DL-tartaric acid. In some embodiments, the coformer compound is mesotartaric acid.

[0183] In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio ranging from 1:0.5 to 1:2.5. In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio ranging from 1:0.6 to 1:2.4, e.g., from 1:0.6 to 1:1.4. In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio ranging from 1:0.7 to 1:1.3 or from 1:0.7 to 1:2.3. In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio ranging from 1:1 to 1:1.5 or from 1:1 to 1:2.5, e.g., from 1:1 to 1:1.3 or from 1:1 to 1:2.3. In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio ranging from 1:1 to 1:1.2 or from 1:1 to 1:2.2. In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio ranging from 1:1 to 1:1.1 or from 1:1 to 1:2.1. In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio of 1:1. In some embodiments, the substituted glycine compound and the coformer of Formula (IA) can be present in the cocrystal in a molecular ratio of 2:1.

[0184] In certain embodiments, the co-crystals described herein are co-crystals of a substituted glycine compound, such as N-methylglycine, with a co-former, wherein the co-former is a compound of formula (IB):

[0185] [ka]

[0186] (In the formula,

[0187] [ka]

[0188] A, B, W, X and Z are as previously described. or a solvate, hydrate, polymorph, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof.

[0189] In formula (IB), in some embodiments, A can be H and B can be H. In some embodiments, A can be OH and B can be H. In some embodiments, A can be H and B can be OH.

[0190] In formula (IB), in certain embodiments, W can be O. In some embodiments, W can be NH. In formula (IB), X can be H in some embodiments. In formula (IB), in certain embodiments, Z can be OH. In some embodiments, Z can be NH. In some embodiments,

[0191] [ka] is C2-C1, where C2 and C1 are linked by a single bond.

[0192] [ka]

[0193] In some embodiments, C2=C1, where C1 and C2 are linked by a double bond.

[0194] [ka]

[0195] In this case, C1 and C2 are both SP 3 or SP 2 It is a coordinated carbon. In some embodiments, the coformer of formula (IB)

[0196] [ka]

[0197] (fumaric acid), and the substituted glycine compound and the coformer are present in the cocrystal in a molecular ratio ranging from 1:2 to 6:1. In some embodiments, the substituted glycine compound and the coformer can be present in the cocrystal in a molecular ratio ranging from 1:1 to 5:1. In some embodiments, the substituted glycine compound and the coformer can be present in the cocrystal in a molecular ratio ranging from 2:1 to 4:1. In some embodiments, the substituted glycine compound and the coformer can be present in the cocrystal in a molecular ratio ranging from 2:1 to 3:1. In some embodiments, the substituted glycine compound and the coformer can be present in the cocrystal in a molecular ratio of 2:1. In some embodiments, the substituted glycine compound and the coformer can be present in the cocrystal in a molecular ratio of 1:1.5. In some embodiments, the substituted glycine compound and the coformer can be present in the cocrystal in a molecular ratio of 1:2.

[0198] In some embodiments, the co-crystal has a powder X-ray diffraction pattern substantially as shown in FIG. 2. In some embodiments, the co-crystal has a powder X-ray diffraction pattern substantially as shown in FIG. 2 and an endothermic peak corresponding to a melting point of about 140° C. In some embodiments, the endothermic peak corresponds to a melting point of about 140° C. In some embodiments, the co-crystal has a powder X-ray diffraction pattern substantially as shown in FIG. 2 and an endothermic peak corresponding to a melting point of about 139° C. In some embodiments, the endothermic peak corresponds to a melting point of about 139° C. In some embodiments, the co-crystal has a powder X-ray diffraction pattern substantially as shown in FIG. 6. In some embodiments, the co-crystal has a powder X-ray diffraction pattern substantially as shown in FIG. 6 and an endothermic peak corresponding to a melting point of about 138° C. In some embodiments, the endothermic peak corresponds to a melting point of about 138° C. In some embodiments, the co-crystal has a powder X-ray diffraction pattern substantially as shown in FIG. 10. In some embodiments, the co-crystal has an X-ray powder diffraction pattern substantially as shown in Figure 10 with an endothermic peak corresponding to a melting point of about 120°C. In some embodiments, the co-crystal has an X-ray powder diffraction pattern substantially as shown in Figure 20. In some embodiments, the co-crystal has an X-ray powder diffraction pattern substantially as shown in Figure 21. In some embodiments, the co-crystal has an X-ray powder diffraction pattern substantially as shown in Figure 22. In some embodiments, the co-crystal has an X-ray powder diffraction pattern substantially as shown in Figure 23.

[0199] In some embodiments, in formula (I), X may be absent. In some embodiments, in formula (I), X may be absent, either R1 or R2 may be absent, and Y and W may be connected by a single bond. In some embodiments, W can be O. In some embodiments, the coformer compound of formula (I) is a compound of formula (IC):

[0200] [ka]

[0201] wherein C1, C2, and Z are as defined above. In some embodiments, the coformer compound has the formula:

[0202] [ka]

[0203] wherein R3 is as defined above. In some embodiments, the coformer compound has the formula:

[0204] [ka]

[0205] (erythorbic acid).

[0206] In some embodiments, the substituted glycine compound and the coformer of Formula (IB) are present in the cocrystal in a molecular ratio ranging from 1:0.5 to 1:1.5, but excluding 1:0.5. In some embodiments, the substituted glycine compound and the coformer of Formula (IB) are present in the cocrystal in a molecular ratio ranging from 1:0.6 to 1:1.4. In some embodiments, the substituted glycine compound and the coformer of Formula (IC) are present in the cocrystal in a molecular ratio ranging from 1:0.7 to 1:1.3. In some embodiments, the substituted glycine compound and the coformer of Formula (IB) are present in the cocrystal in a molecular ratio ranging from 1:1 to 1:1.5. In some embodiments, the substituted glycine compound and the coformer of Formula (IC) are present in the cocrystal in a molecular ratio of 1:1 to 1:1.3. In some embodiments, the substituted glycine compound and the coformer of Formula (IC) are present in the cocrystal in a molecular ratio of 1:1 to 1:1.2. In some embodiments, the substituted glycine compound and the coformer of Formula (IC) can be present in the cocrystal in a molar ratio of 1:1 to 1:1.1. In some embodiments, the substituted glycine compound and the coformer of Formula (IC) can be present in the cocrystal in a molar ratio of 1:1.

[0207] Synthesis method In some embodiments, the synthesis of a co-crystal of a substituted glycine compound and a coformer compound of Formula (I) includes a first step of mixing the substituted glycine compound with the coformer of Formula (I), followed by a step of heating and stirring the solution, a step of cooling and stirring the solution, and a step of collecting the co-crystal thus formed. In some embodiments, the first step of synthesizing a co-crystal of a substituted glycine compound and a coformer of Formula (I) involves mixing the substituted glycine compound and the coformer at a temperature of about 40-110°C to form a saturated solution, wherein the substituted glycine and the coformer are in a molar ratio of 10:1 to 1:10. In some embodiments, the substituted glycine and the coformer are mixed at a temperature of 40-50°C to form the saturated solution. In some embodiments, the substituted glycine and the coformer are mixed at a temperature of 40-60°C to form the saturated solution. In some embodiments, the substituted glycine and the coformer are mixed at a temperature of 40-80°C to form the saturated solution. In some embodiments, the substituted glycine and coformer are mixed at a temperature of 40-100°C to form a saturated solution. In some embodiments, the substituted glycine and coformer are mixed at a temperature of 50-110°C to form a saturated solution. In some embodiments, the substituted glycine and coformer are mixed at a temperature of 50-100°C to form a saturated solution. In some embodiments, the substituted glycine and coformer are mixed at a temperature of 60-110°C to form a saturated solution. In some embodiments, the substituted glycine and coformer are mixed at a temperature of 80-110°C to form a saturated solution. In some embodiments, the substituted glycine and coformer are mixed at a molecular ratio of 10:1 to 1:10. In some embodiments, the substituted glycine and coformer are mixed at a molecular ratio of 8:1 to 1:8. In some embodiments, the substituted glycine and coformer are present in a molar ratio ranging from 6:1 to 1:6 (e.g., 6:1 to 3:1). In some embodiments, the substituted glycine and coformer are present in a molar ratio ranging from 5:1 to 1:5. In some embodiments, the substituted glycine and coformer are present in a molar ratio ranging from 4:1 to 1:4. In some embodiments, the substituted glycine and coformer are present in a molar ratio ranging from 3:1 to 1:3 (e.g., 3:1 to 1:1).In some embodiments, the substituted glycine and coformer are present in a molar ratio ranging from 2:1 to 1:2. In some embodiments, the substituted glycine and coformer are present in a molar ratio of 1:1 or 2:1.

[0208] In certain embodiments, the second step of synthesizing a cocrystal of a substituted glycine compound and a coformer compound of Formula (I) involves heating and stirring the solution at a temperature of about 40 to 110°C. In certain embodiments, in the second step of synthesizing the cocrystal, the solution is heated and stirred at a temperature of about 40 to 110°C for about 1 to 10 hours. In some embodiments, in the second step of synthesizing the cocrystal, the solution is heated and stirred at a temperature of about 50 to 110°C. In some embodiments, in the second step of synthesizing the cocrystal, the solution is heated and stirred to a temperature of about 60 to 110°C. In some embodiments, in the second step of synthesizing the cocrystal, the solution is heated and stirred to a temperature of about 70 to 110°C. In some embodiments, in the second step of synthesizing the cocrystal, the solution is heated and stirred to a temperature of about 100 to 110°C. In some embodiments, in the second step of synthesizing the cocrystal, the solution is heated and stirred for about 1 to 5 hours, about 1 to 10 hours, about 1 to 15 hours, or about 1 to 20 hours.

[0209] In certain embodiments, the third step in the synthesis of a co-crystal of a substituted glycine and a coformer compound of Formula (I) (e.g., Formula IA, IB, or IC) involves cooling and stirring the solution at a temperature of about 10°C to about 30°C to form the co-crystal. In certain embodiments, in the third step in the synthesis of the co-crystal, the solution is cooled and stirred at a temperature of about 4°C to about 30°C for about 10 to about 36 hours. In certain embodiments, in the third step in the synthesis of the co-crystal, the solution is cooled to a temperature of about 15°C to about 30°C and stirred. In certain embodiments, in the third step in the synthesis of the co-crystal, the solution is cooled to a temperature of about 20°C to about 30°C and stirred. In certain embodiments, in the third step in the synthesis of the co-crystal, the solution is cooled to a temperature of about 25°C and stirred. In certain embodiments, in the third step in the synthesis of the co-crystal, the solution is cooled to a temperature of about 4°C, about 5°C, about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, or about 35°C and stirred. In certain embodiments, in the third step of the co-crystal synthesis, the solution is cooled and stirred for about 5 to 40 hours, about 5 to 36 hours, about 5 to 30 hours, about 10 to 36 hours, about 10 to 30 hours, or about 10 to 25 hours. In certain embodiments, the final step in the synthesis of a co-crystal of a substituted glycine and a coformer compound of Formula (I) is recovering the co-crystal formed in the third step.

[0210] Any of the above co-crystals can be prepared by a method involving heating a saturated solution followed by cooling.

[0211] In some embodiments, crystallization can be achieved by heating a saturated solution followed by cooling. The substituted glycine and co-crystal former (coformer) are mixed in a molar ratio ranging from 10:1 to 1:10 and placed in a round-bottom flask placed in a water bath at room temperature or elevated temperature (e.g., 60-65°C). A solvent (e.g., methanol, ethanol, etc.) can be added dropwise, e.g., via a dropping funnel, to the flask, and the resulting solution stirred until all powder is completely dissolved. The mixture can be first heated and stirred at approximately 45-55°C, then cooled and stirred at approximately 20-25°C to allow co-crystal formation. The co-crystals can be recovered by suction filtration, and the mother liquor can be washed, if necessary, before being dried overnight at room temperature or at elevated temperature in an oven.

[0212] composition The present disclosure provides compositions comprising a cocrystal described herein and a carrier. In certain embodiments, the carrier is a pharmaceutically acceptable excipient. In certain embodiments, the compositions described herein comprise a cocrystal of the present invention and a carrier. The compositions described herein are useful for treating and / or reducing the risk of neuropsychiatric disorders or disorders of glucose or lipid metabolism.

[0213] In certain embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition is a nutraceutical composition. In some embodiments, the compositions described herein can be health foods or health food products, which can be any type of liquid or solid / semi-solid material, and are used to provide nutrition to humans or animals, improve basic behavioral functions, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and / or cognitive function, or facilitate the treatment of any of the target diseases described herein (e.g., neuropsychiatric disorders or glucose or lipid metabolism disorders, including those described herein). Health foods can be foods (e.g., tea-based beverages, juices, soft drinks, coffee, milk, jellies, cookies, cereals, chocolates, snack bars, herbal extracts, dairy products (e.g., ice cream and yogurt)), food / nutraceutical supplements, or nutraceutical formulations.

[0214] The health foods described herein may include an edible carrier that provides one or more benefits to the product, as described herein. Examples of edible carriers include starch, cyclodextrin, maltodextrin, methylcellulose, carbomethoxycellulose, xanthan gum, and aqueous solutions thereof. Other examples include solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonicity agents, absorption delaying agents, stabilizers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and other materials known to those skilled in the art, as well as combinations thereof. In some examples, the health foods described herein may further include a neuroprotective food, such as fish oil, flaxseed oil, and / or benzoates.

[0215] In some examples, the health food is a nutraceutical composition, which refers to a composition that includes ingredients from food sources but provides additional health benefits beyond basic nutritional value. The nutraceutical compositions described herein include a cocrystal described herein (e.g., a cocrystal of a substituted glycine compound with a coformer described herein) and additional ingredients and supplements that promote health and / or enhance the stability and bioactivity of the cocrystal.

[0216] The effects of the nutraceutical composition may be rapid and / or short-term, or may help achieve long-term health goals such as those described herein, for example, improving basic behavioral function, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory, and / or cognitive function in human subjects with or at risk of neuropsychiatric disorders or glucose or lipid metabolism disorders. The nutraceutical composition can be included in edible materials, for example, as a dietary supplement or pharmaceutical formulation. Dietary supplements may contain additional nutrients, such as vitamins, minerals, or amino acids. The composition can also be a beverage or food product, such as tea, soft drinks, juice, milk, coffee, cookies, cereal, chocolate, or snack bar. If desired, the composition can be sweetened by adding sweeteners such as sorbitol, maltitol, hydrogenated glucose syrup, hydrogenated starch hydrolysate, high-fructose corn syrup, cane sugar, beet sugar, pectin, or sucralose.

[0217] The dietary supplement compositions disclosed herein may be in the form of a solution. For example, the dietary supplement formulation may be provided in a medium such as a buffer, solvent, diluent, inert carrier, oil, or cream. In some instances, the formulation is in an aqueous solution, optionally containing a non-aqueous cosolvent such as alcohol. The dietary supplement composition may also be in the form of a powder, paste, jelly, capsule, or tablet. Lactose and cornstarch are commonly used as diluents for capsules and carriers for tablets. Lubricants such as magnesium stearate are typically added to form tablets.

[0218] Health foods can be formulated, for example, for oral administration, according to a suitable route of administration.For oral administration, the composition can be, for example, in the form of tablets or capsules, and these formulations can be prepared by conventional means using acceptable excipients, such as binders (for example, pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropylmethylcellulose); fillers (for example, lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc, or silica); disintegrants (for example, potato starch, or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulfate).Tablets can be coated by methods well known in the art.Bars and other chewable formulations are also included.

[0219] In some instances, the health food may be in a liquid form, and one or more edible carriers may be solvents or dispersion media, such as, but not limited to, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), lipids (e.g., triglycerides, vegetable oils, liposomes), or combinations thereof. Suitable fluidity can be maintained by, for example, using a coating such as lecithin; maintaining the required particle size by, for example, dispersion in a carrier such as a liquid polyol or lipid; using surfactants such as hydroxypropylcellulose; or a combination thereof. In many cases, it may be advisable to include isotonic agents, such as sugars, sodium chloride, or combinations thereof.

[0220] Liquid preparations for oral administration can be in the form of, for example, solutions, syrups or suspensions, or they can be provided as dry products for reconstitution with water or other suitable vehicles before use.In one embodiment, liquid preparations can be formulated for administration with fruit juice.Such liquid preparations can be prepared by conventional means using pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifiers (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl p-hydroxybenzoates, benzoates or sorbates).

[0221] In certain embodiments, the composition is a medical food. A medical food is a food formulated to be consumed or administered enterally. Such foods are typically used under the supervision of a physician for the specific dietary management of a target disease, such as those described herein. In some cases, such medical food compositions are specially formulated and processed (unlike natural foodstuffs used in their natural state) for patients in need of treatment (e.g., human patients suffering from diseases or who require the use of a product as a primary active agent to improve a disease or condition through a specific dietary management). In some instances, the medical food compositions described herein are not simply one of those recommended by a physician as part of a comprehensive dietary management to manage symptoms or reduce the risk of a disease or condition.

[0222] The medical food compositions described herein, comprising a substituted glycine compound and a coformer of Formula (I) and at least one carrier (e.g., those described herein), can be in the form of a solution; a powder, a bar, a wafer, a suspension in a suitable liquid, or a suitable emulsion, as described in detail below. The at least one carrier, either natural or synthetic (non-natural), may impart one or more benefits, such as stability, bioavailability, and / or bioactivity, to the substituted glycine compound and coformer in the composition. Any of the carriers described herein can be used to prepare a medical food composition. In some embodiments, the medical food composition may further comprise one or more additional ingredients selected from the group including, but not limited to, natural flavors, artificial flavors, major trace and ultratrace minerals, minerals, vitamins, oats, nuts, spices, milk, eggs, salt, wheat flour, lecithin, xanthan gum, and / or sweeteners. The medical food composition may be packaged in a suitable container and may further comprise at least one additional therapeutic agent, such as those described herein.

[0223] In certain embodiments, the cocrystals described herein are provided in an effective amount in a pharmaceutical composition. In certain embodiments, the effective amount is a therapeutically effective amount (e.g., an amount effective to treat and / or reduce the risk of a neuropsychiatric disorder or a glucose or lipid metabolism disorder in a subject in need of treatment). In certain embodiments, the neuropsychiatric disorder is a neurological disorder, such as Alzheimer's disease. In certain embodiments, the glucose or lipid metabolism disorder is obesity. In certain embodiments, the effective amount is a prophylactically effective amount (e.g., an amount effective to prevent a neuropsychiatric disorder or a glucose or lipid metabolism disorder in a subject in need of treatment).

[0224] The pharmaceutical compositions described herein may be prepared by any method known in the art of pharmacology. In general, such methods of preparation include bringing into association a cocrystal described herein (i.e., the "active ingredient") with the carrier or excipient, and / or one or more other accessory ingredients, and then, if necessary and / or desired, shaping and / or packaging the product into a desired single- or multi-dose unit.

[0225] Pharmaceutical compositions can be prepared, packaged, and / or sold in bulk as a unit dose and / or as a plurality of unit doses. A "unit dose" is a discrete amount of a pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dose of the active ingredient that would be administered to a subject and / or a convenient fraction, such as 1 / 2 or 1 / 3 of such a dose.

[0226] The relative amounts of the active ingredient, pharmaceutically acceptable excipient, and / or any additional ingredients in the pharmaceutical compositions described herein will vary depending on the identity, size, and / or condition of the subject being treated, and further depending on the route by which the composition will be administered. The compositions can contain from 0.1% to 100% (w / w) of the active ingredient.

[0227] Pharmaceutically acceptable excipients used in the preparation of the pharmaceutical compositions provided herein include inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants, and / or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening agents, flavoring agents, and perfuming agents may also be present in the compositions.

[0228] Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, fatty acid esters of polyethylene glycol and sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions may contain adjuvants such as wetting agents, emulsifying agents, and suspending agents, sweeteners, flavorings, and aromatics. In certain embodiments for parenteral administration, the conjugates described herein are mixed with a solubilizing agent, such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.

[0229] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can be sterile injectable solutions, suspensions, or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, solutions in 1,3-butanediol. Among the acceptable excipients and solvents, water, Ringer's solution, and isotonic saline, as defined by the US Pharmacopoeia, can be used. Furthermore, sterile fixed oils can be conveniently used as solvents or suspending media. For this purpose, any brand of fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid, can also be used in injectable preparations.

[0230] Injectable preparations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by including a sterilizing agent in the form of a sterile solid composition, which can be dissolved or dispersed in sterile purified water or other sterile injectable medium before use.

[0231] To prolong the effect of a drug, it is often desirable to delay the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug depends on its dissolution rate, which in turn may depend on the size and crystalline form of the crystals. Alternatively, delayed absorption of a parenterally administered dosage form can be achieved by dissolving or suspending the drug in an oil vehicle.

[0232] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is present in at least one inert pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or (a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; (c) humectants, such as glycerol; (d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (e) solution retarders, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) humectants, such as cetyl alcohol and glycerol monostearate; (h) absorbents, such as kaolin and bentonite earth; and (i) It is mixed with lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

[0233] Solid compositions of a similar type can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmacological arts. They can optionally contain opacifying agents, or can be of a composition that releases the active ingredient(s) preferentially only in a certain part of the gastrointestinal tract, optionally in a delayed manner. Examples of encapsulating compositions that can be used are polymeric substances and waxes. Solid compositions of a similar type can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.

[0234] The active ingredient may also be in microencapsulated form with one or more excipients, as described above. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, controlled-release (sustained-release) coatings, and other coatings well known in the pharmaceutical formulation art. In such solid dosage forms, the active ingredient may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. Such dosage forms may contain, as is common practice, additional substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms may contain buffering agents. They may optionally contain opacifying agents, or may be of a composition that releases the active ingredient preferentially, optionally in a delayed manner, only in a certain part of the gastrointestinal tract. Examples of encapsulating agents that can be used include, but are not limited to, polymeric substances and waxes.

[0235] Although the description of pharmaceutical compositions provided herein is directed primarily to pharmaceutical compositions suitable for administration to humans, such compositions are generally suitable for administration to animals of all kinds. The modification of pharmaceutical compositions suitable for administration to humans into compositions suitable for administration to a variety of animals is well understood, and a veterinary pharmacologist of ordinary skill can design and / or perform such modifications with routine experimentation.

[0236] The cocrystals provided herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage. However, it will be understood that the total daily usage amount of the compositions described herein will be determined by a physician within the scope of sound medical judgment. The specific therapeutically effective amount level for any particular subject or organism will depend on various factors, including the severity of the disease or disorder being treated; the activity of the specific active ingredient used; the specific composition used; the age, weight, general health, sex and diet of the subject; the timing, route of administration and excretion rate of the specific active ingredient used; the duration of treatment; drugs used in combination or simultaneously with the specific active ingredient used; and similar factors well known in the medical field.

[0237] Also encompassed by the present disclosure are kits (e.g., pharmaceutical packages). The provided kits can include a pharmaceutical composition or cocrystal described herein and a container (e.g., a vial, an ampoule, a bottle, a syringe and / or a dispenser package, or other suitable container). In some embodiments, the provided kits can optionally further include a second container containing a pharmaceutical excipient for diluting or suspending the pharmaceutical composition or cocrystal described herein. In some embodiments, the first container and the pharmaceutical composition or cocrystal described herein provided in the second container are combined together to form a single dosage form (single dose).

[0238] In certain embodiments, the kits described herein comprise a first container containing a cocrystal or composition described herein. In certain embodiments, the kits described herein are useful for treating and / or reducing the risk of a neuropsychiatric disorder, or for treating and / or reducing the risk of a glucose or lipid metabolism disorder in a subject in need thereof.

[0239] In certain embodiments, the kits described herein further include instructions for using the cocrystal or composition included in the kit. The kits described herein may also include information required by regulatory authorities, such as the U.S. Food and Drug Administration (FDA). In some embodiments, the information included in the kit is prescribing information. In some embodiments, the kit and instructions are provided for treating and / or reducing the risk of a neuropsychiatric disorder or a glucose or lipid metabolism disorder in a subject in need of treatment. The kits described herein may also include one or more additional agents described herein as separate compositions.

[0240] Treatment method The present disclosure provides a method for treating and / or reducing the risk of a neuropsychiatric disorder or a glucose or lipid metabolism disorder, comprising administering to a subject in need thereof an effective amount (e.g., a therapeutically effective amount) of a cocrystal or composition thereof described herein.

[0241] Another aspect of the present disclosure provides a method for preventing a neuropsychiatric disorder or a glucose or lipid metabolism disorder, comprising administering to a subject in need thereof an effective amount (e.g., a prophylactically effective amount) of a cocrystal or composition thereof described herein.

[0242] The cocrystals and compositions described herein are useful for treating and / or preventing neuropsychiatric disorders or disorders of glucose or lipid metabolism. In certain embodiments, the neuropsychiatric disorder is schizophrenia. In certain embodiments, the neuropsychiatric disorder is a psychotic disorder. In certain embodiments, the neuropsychiatric disorder is Alzheimer's disease. In certain embodiments, the neuropsychiatric disorder is frontotemporal dementia. In certain embodiments, the neuropsychiatric disorder is dementia. In certain embodiments, the neuropsychiatric disorder is mild cognitive impairment. In certain embodiments, the neuropsychiatric disorder is benign amnesia. In certain embodiments, the neuropsychiatric disorder is closed head injury. In certain embodiments, the neuropsychiatric disorder is an autism spectrum disorder, such as Asperger's disorder. In certain embodiments, the neuropsychiatric disorder is attention deficit disorder. In certain embodiments, the neuropsychiatric disorder is obsessive-compulsive disorder. In certain embodiments, the neuropsychiatric disorder is a tic disorder. In certain embodiments, the neuropsychiatric disorder is a childhood learning disorder. In certain embodiments, the neuropsychiatric disorder is premenstrual syndrome. In certain embodiments, the neuropsychiatric disorder is depression, such as associated with dysthymia or bereavement. In certain embodiments, the neuropsychiatric disorder is suicidal ideation and / or suicidal behavior. In certain embodiments, the neuropsychiatric disorder is bipolar disorder, including bipolar I disorder and bipolar II disorder. In certain embodiments, the neuropsychiatric disorder is an anxiety disorder, including panic and phobia disorder. In certain embodiments, the neuropsychiatric disorder is post-traumatic stress disorder. In certain embodiments, the neuropsychiatric disorder is chronic pain. In certain embodiments, the neuropsychiatric disorder is an eating disorder, including bulimia and anorexia nervosa. In certain embodiments, the neuropsychiatric disorder is an addictive disorder, including drug dependence and substance abuse. In certain embodiments, the neuropsychiatric disorder is a personality disorder. In certain embodiments, the neuropsychiatric disorder is Parkinson's disease. In certain embodiments, the neuropsychiatric disorder is Huntington's disease. In certain embodiments, the neuropsychiatric disorder is amyotrophic lateral sclerosis. In certain embodiments, the glucose or lipid metabolism disorder is obesity. In certain embodiments, the glucose or lipid metabolism disorder is diabetes.In certain embodiments, the glucose or lipid metabolism disorder is hypercholesterolemia. In certain embodiments, the glucose or lipid metabolism disorder is hyperlipidemia. In certain embodiments, the glucose or lipid metabolism disorder is hypertension.

[0243] In certain embodiments, the methods described herein further comprise administering an additional agent to the subject. In certain embodiments, the methods described herein further comprise contacting a biological sample with the additional agent. In certain embodiments, the methods described herein further comprise contacting a tissue with the additional agent. In certain embodiments, the methods described herein further comprise contacting a cell with the additional agent.

[0244] The cocrystals and compositions provided herein can be administered by any route, for example, enteral (e.g., oral), parenteral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intracerebroventricular, transdermal, intradermal, subcutaneous, intradermal, rectal, vaginal, intraperitoneal, or topical (such as by powders, ointments, creams, and / or drops). Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), local administration via the blood and / or lymphatic supply, and / or direct administration to the trunk. Generally, the most appropriate route of administration will depend on various factors, including the properties of the agent (e.g., its stability in the gastrointestinal environment) and / or the condition of the subject (e.g., whether the subject can tolerate oral administration).

[0245] The exact amount of cocrystal required to achieve an effective dose will vary from subject to subject, depending, for example, on the subject's species, age, and general condition, the severity of side effects or disease, the identity of the particular cocrystal, the mode of administration, etc. An effective amount can be contained in a single dose (e.g., a single oral dose) or multiple doses (e.g., multiple oral doses). In certain embodiments, when multiple doses are administered to a subject or applied to a biological sample, tissue, or cell, any two doses of the multiple doses contain different or substantially the same amounts of a cocrystal described herein. In certain embodiments, when multiple doses are administered to a subject or to a biological sample, tissue, or cell, the frequency with which the multiple doses are administered to the subject or applied to the tissue or cell is three times per day, two times per day, one day, one every other day, one every three days, one week, one every two weeks, one month, or one every other month. In certain embodiments, when multiple doses are administered to a subject or applied to a biological sample, tissue or cell, the frequency of administration is once a day.In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, the frequency of administration is twice a day.In certain embodiments, the period between the first and last administration of multiple doses is 1 day, 2 days, 4 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, 7 years, 10 years, 15 years, 20 years, or the life span of a subject, biological sample, tissue or cell.In certain embodiments, the period between the first and last administration of multiple doses is 3 months, 6 months, or 1 year.In certain embodiments, the period between the first and last administration of multiple doses is the life span of a subject, biological sample, tissue or cell. In certain embodiments, the dosage amounts described herein (e.g., either single or multiple doses) independently contain between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g (inclusive) of a cocrystal described herein.In certain embodiments, the dosage amounts described herein independently comprise between 3 mg and 10 mg, inclusive, of a cocrystal described herein. In certain embodiments, the dosage amounts described herein independently comprise between 10 mg and 30 mg, inclusive, of the cocrystal. In certain embodiments, the dosage amounts described herein independently comprise between 30 mg and 100 mg, inclusive, of the cocrystal. In certain embodiments, the dosage amounts described herein independently comprise between 100 mg and 300 mg, inclusive, of the cocrystal. In certain embodiments, the dosage amounts described herein independently comprise between 300 mg and 1000 mg, inclusive, of the cocrystal.

[0246] The dosage ranges described herein provide guidance for administration of the pharmaceutical compositions to adults. The amount to be administered to, for example, children or adolescents, can be determined, for example, by a medical professional or person skilled in the art, and can be less than or the same as the amount administered to an adult.

[0247] The cocrystals or compositions described herein can be administered in combination with one or more additional agents (e.g., therapeutically and / or prophylactically active agents) useful for treating and / or reducing the risk of a neuropsychiatric disorder or glucose or lipid metabolism. The cocrystals or compositions can be administered in combination with additional agents to improve their activity (e.g., activity (e.g., potency and / or efficacy) for treating and / or reducing the risk of a neuropsychiatric disorder or glucose or lipid metabolism in a subject in need thereof), enhance bioavailability, increase safety, reduce drug resistance, reduce and / or modify metabolism, inhibit excretion, and / or modify distribution in a subject, biological sample, tissue, or cell. It will be understood that the treatments used can achieve desired effects on the same disease and / or they may achieve different effects. In certain embodiments, the pharmaceutical compositions comprising the cocrystals described herein and additional agents exhibit a synergistic effect that is not present in pharmaceutical compositions comprising the cocrystal and one of the additional agents but not both.

[0248] The cocrystal or composition can be administered simultaneously with, before, or after one or more additional agents, which may be useful, for example, as a combination therapy for treating and / or reducing the risk of a neuropsychiatric disorder or a glucose or lipid metabolism disorder in a subject. Such agents include therapeutically active agents. They also include prophylactically active agents. Agents include organic small molecules, such as medicinal compounds or cocrystals thereof (e.g., compounds approved for human or veterinary use by the U.S. Food and Drug Administration, as set forth in the U.S. Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins such as antibodies, glycoproteins, steroids, nucleic acids, DNA, RNA, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. In certain embodiments, the additional agent is a drug approved by a regulatory agency (e.g., the U.S. FDA) for treating and / or reducing the risk of a neuropsychiatric disorder or a glucose or lipid metabolism disorder in a subject. Each additional agent can be administered at a dose and / or time schedule determined for that agent. The additional agents may be administered together with each other and / or with the cocrystals or compositions described herein in a single dose or individually in different doses. The particular combination to use in the dosing regimen will take into account the compatibility of the cocrystals of the invention with the additional agent(s) and / or the desired therapeutic and / or prophylactic effect to be achieved. In general, it is expected that the additional agent(s) used in combination will be used at levels that do not exceed the levels at which they are used individually. In some embodiments, the levels used in combination will be lower than the levels used individually.

[0249] In certain embodiments, the additional agent is an agent for treating and / or reducing the risk of a neuropsychiatric disorder, an agent for treating and / or reducing the risk of a glucose or lipid metabolism disorder, or a combination thereof. In certain embodiments, a cocrystal or pharmaceutical composition described herein is administered in combination with a therapy for treating and / or reducing the risk of a neuropsychiatric disorder or a glucose or lipid metabolism disorder.

[0250] Without further elaboration, it is believed that one skilled in the art can, based on the preceding description, utilize the present invention to its fullest extent. The following specific embodiments, therefore, should be understood to be merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference for the purposes and subject matter referred to herein. [Example]

[0251] In order that this disclosure may be more fully understood, the following examples are set forth: The synthetic and biological examples described herein are offered to illustrate, but in no way should be construed as limiting the scope of, the co-crystals, compounds, compositions and methods provided herein.

[0252] The following is an exemplary method for preparing the co-crystals described herein. Example 1 Preparation of N-methylglycine:D-tartaric acid (1:1 cocrystal) by heating in saturated solution followed by cooling

[0253] N-methylglycine (5.0 g, 56.1 mmol) and D-tartaric acid (10.1 g, 67.3 mmol) were placed in 62 mL of methanol and stirred at 50°C until all reagents dissolved. The solution was stirred at 50°C for an additional 5 hours and then cooled to room temperature overnight, causing precipitation of a solid. After precipitation subsided, the solution was filtered and the collected solid was dried under vacuum at room temperature for 24 hours to yield 11.0 g of N-methylglycine:D-tartaric acid (1:1) cocrystal. The resulting cocrystal was purified as described below. 1The compounds were analyzed by H-NMR, powder X-ray diffraction, and thermal analysis.

[0254] Thermogravimetric analysis (TGA): TGA data were measured on a Pyris 1 TGA (Perkin Elmer) using platinum crucibles over the temperature range of 50°C–700°C at a heating rate of 10°C / min.

[0255] Differential scanning calorimetry: The melting points of the cocrystals were measured using differential scanning calorimetry (DSC). DSC data were measured using a DSC 25 (TA Instruments) with a T-zero (thermally stable) aluminum low-mass evaporating dish at a heating rate of 10°C / min and in the heating range of 40°C–230°C.

[0256] X-ray powder diffraction (XRPD): X-ray diffraction patterns were obtained on a D8 ADVANCE (Bruker AXS GmbH, Germany) instrument. Samples were scanned in continuous mode from 0 to 45° (2θ) with a step width of 0.02° using Cu-Kα radiation on a rotary stage at 40 kV and 40 mA. The incident beam path was equipped with a 0.2 mm divergence slit and a 0.02 mm air scattering screen. The diffracted beam was fitted with a nickel filter. Detection was performed using a Lynxeye detector (Bruker AXS).

[0257] · 1 H-NMR: 1 H-nuclear magnetic resonance (NMR) analyses were carried out on a Bruker Fourier 400 (Bruker) in deuterated solvents such as d-methanol or DO at 25° C. NMR for Figures 1, 5, 9, and 13 was carried out in DO at 25° C.

[0258] The cocrystal obtained by the method described in Example 1 1 The results of H-NMR, powder X-ray diffraction, and thermal analysis are shown in Figures 1 to 4, respectively.

[0259] Example 2 : Preparation of N-methylglycine:L-tartaric acid (1:1 cocrystal) by heating in saturated solution followed by cooling

[0260] N-methylglycine (5.0 g, 56.1 mmol) and L-tartaric acid (10.1 g, 67.3 mmol) were added to 62 mL of methanol, and the resulting slurry was stirred at 50°C until all reagents were dissolved. The mixture was stirred at 50°C for 5 hours and cooled to room temperature overnight to precipitate a solid. The solid was then collected by filtration and dried under vacuum at room temperature for 24 hours to yield 11.0 g of N-methylglycine:L-tartaric acid (1:1) cocrystal. The cocrystal obtained by the method described in Example 2 1 The results of H-NMR, powder X-ray diffraction, and thermal analysis are shown in Figures 5 to 8, respectively.

[0261] Example 3 : Preparation of N-methylglycine:DL-tartaric acid (1:1) cocrystals by heating in saturated solution followed by cooling N-methylglycine (5.0 g, 56.1 mmol) and DL-tartaric acid (12.6 g, 84.0 mmol) were added to 75 mL of methanol at 50°C, and the mixture was stirred until all reagents were dissolved. The resulting solution was stirred at 50°C for an additional 5 hours and then cooled to room temperature overnight to form a solid. The solid was isolated by filtration and dried under vacuum at room temperature for 24 hours to obtain 10 g of N-methylglycine:DL-tartaric acid 1:1 cocrystal. The cocrystal obtained by the method described in Example 3 1 The results of H-NMR, powder X-ray diffraction and thermal analysis are shown in Figures 9 to 12, respectively.

[0262] Example 4 Preparation of N-methylglycine:L-tartaric acid (2:1 cocrystal) N-methylglycine (25.0 g, 280.6 mmol) and L-tartaric acid (21.0 g, 139.9 mmol) were added to 140 mL of 60% ethanol / water. The mixture was stirred at 40°C until all reagents were dissolved, then cooled to 30°C for the addition of seed crystals. The mixture was further cooled to 4°C, followed by the addition of 420 mL of ethanol, and the resulting solution was stirred overnight. The solution was then returned to 25°C and further stirred overnight. The formed solid was collected by filtration and dried under vacuum at room temperature for 24 hours to yield N-methylglycine:L-tartaric acid (2:1) cocrystals. The resulting cocrystals were visualized as follows: 1 H-NMR, powder X-ray diffraction and thermal analysis were performed.

[0263] Example 5 Hygroscopicity Test of N-Methylglycine:L-Tartaric Acid (1:1 Co-Crystal) vs. N-Methylglycine:L-Tartaric Acid (2:1 Co-Crystal) - Condition 1 100 mg each of N-methylglycine:L-tartaric acid (1:1 co-crystal) and N-methylglycine:L-tartaric acid (2:1 co-crystal) were exposed to high humidity conditions (70-75% RH) at room temperature for 3 days. The results showed that the 1:1 co-crystal remained as a fine white powder, while the 2:1 co-crystal became wet and turned into a somewhat sticky white solid (Figure 17). This result demonstrates that the 1:1 co-crystal is much less hygroscopic than the 2:1 co-crystal.

[0264] Example 6 Hygroscopicity test of N-methylglycine:tartaric acid cocrystal - Condition 2 100-150 mg each of N-methylglycine:L-tartaric acid 1:1 cocrystal, N-methylglycine:DL-tartaric acid 1:1 cocrystal, N-methylglycine:L-tartaric acid 2:1 cocrystal, N-methylglycine:DL-tartaric acid 2:1 cocrystal, and N-methylglycine were weighed and placed in vials in a humidity chamber at 30°C and 75% RH. The weight changes of each cocrystal were measured at 1, 2, 3, 5, 24, 48, and 72 hours and are listed in Table 1 below.

[0265] Table 1. Hygroscopicity studies of various N-methylglycine:tartaric acid cocrystals

[0266] [Table 1]

[0267] The results show that after 72 hours, the 1:1 N-methylglycine:L-tartaric acid cocrystal absorbed only 0.6% water and remained as a white powder, whereas the 2:1 N-methylglycine:L-tartaric acid cocrystal absorbed approximately 1.1% water and partially converted to a liquid. This indicates that the 1:1 cocrystal is significantly more hygroscopic than the 2:1 cocrystal, as shown in Figure 18. In summary, the 1:1 N-methylglycine:tartaric acid cocrystal is much less hygroscopic than the 2:1 N-methylglycine:tartaric acid cocrystal, which is much less hygroscopic than the 2:1 N-methylglycine:L-tartaric acid cocrystal, while the 1:1 N-methylglycine:DL-tartaric acid cocrystal is much less hygroscopic than the 2:1 N-methylglycine:DL-tartaric acid cocrystal.

[0268] Furthermore, after 5 h, the 1:1 N-methylglycine:DL-tartaric acid cocrystal absorbed 18.7% of the water and began to partially liquidize, whereas the N-methylglycine:L-tartaric acid cocrystal absorbed only 0.4% of the water, indicating that the single enantiomeric coformers, i.e., cocrystals of N-methylglycine with either D- or L-tartaric acid, are less hygroscopic than the racemic coformer, i.e., cocrystals of DL-tartaric acid with N-methylglycine.

[0269] Example 7 Hygroscopicity test of N-methylglycine:tartaric acid 2:1 cocrystal - Condition 3 The hygroscopicity of each of N-methylglycine, N-methylglycine:DL-tartaric acid 2:1 cocrystal, N-methylglycine:D-tartaric acid 2:1 cocrystal, and N-methylglycine:L-tartaric acid 2:1 cocrystal was measured by dynamic vapor sorption on a DVS Advantage (Surface Measurement Systems Ltd., London) for comparison. Measurements were taken at 25 °C from 0 to 90% to 0% RH in 10% RH increments per step, with equilibration set at dm / dt = +0.01% / min for 10 or 180 min / step. All samples reached equilibrium at each step before reaching the maximum set point of 180 min. The results are summarized in the table below. Table 2. Hygroscopicity study of N-methylglycine:tartaric acid 2:1 cocrystal

[0270] [Table 2]

[0271] The results show that when the RH increased to 70%, the N-methylglycine:D-tartaric acid 2:1 cocrystal and the N-methylglycine:L-tartaric acid 2:1 cocrystal absorbed only 0.31% and 0.18% water, respectively, compared to 3.12% for the N-methylglycine:DL-tartaric acid 2:1 cocrystal. At 90% RH, the N-methylglycine:L-tartaric acid 2:1 cocrystal absorbed 10.74% water, compared to 14.27% and 30.35% for the 2:1 D-tartaric acid and DL-tartaric acid cocrystals. In summary, the N-methylglycine and L-tartaric acid cocrystal was least hygroscopic compared to the D-tartaric acid and DL-tartaric acid cocrystals. At the same time, the L-tartaric acid cocrystal was much less hygroscopic than the D-tartaric acid cocrystal.

[0272] Example 8 Hygroscopicity test of N-methylglycine, L-tartaric acid, and N-methylglycine:L-tartaric acid 1:1 cocrystal - Condition 4 The hygroscopicity of each of N-methylglycine, L-tartaric acid, and the N-methylglycine:L-tartaric acid 1:1 cocrystal was measured by dynamic vapor sorption on a DVS Advantage (Surface Measurement Systems Ltd., London) for comparison. Measurements were taken at 25 °C from 0 to 70 to 0% RH in 10% RH increments per step, with equilibration set at dm / dt = +0.01% / min for 10 or 180 min / step. All samples reached equilibrium at each step before reaching the maximum set point of 180 min. The results, shown in Figure 19, indicated that the N-methylglycine:L-tartaric acid 1:1 cocrystal was less hygroscopic than either N-methylglycine or L-tartaric acid individually.

[0273] Example 9 Melting point of the cocrystal of N-methylglycine and tartaric acid The melting points of the 1:1 and 2:1 cocrystals of N-methylglycine with L-tartaric acid, D-tartaric acid, and DL-tartaric acid were measured by DSC and are summarized in Table 3. It was clear that the 1:1 and 2:1 cocrystals of N-methylglycine with a single enantiomeric coformer (i.e., D- or L-tartaric acid) exhibited higher melting points than the cocrystal with the racemic coformer (i.e., DL-tartaric acid) and were therefore more stable under thermal stress at high temperatures.

[0274] [Table 3]

[0275] Example 10 : Comparison of aqueous solubility of N-methylglycine and tartaric acid cocrystal versus N-methylglycine

[0276] After weighing 0.1–1.0 g of each sample, water was gradually added to determine the maximum solubility. The solubilities of the 1:1 and 2:1 cocrystals of N-methylglycine and L-tartaric acid were 1250 g / L and 1121 g / L, respectively, which were higher than the 660 g / L of N-methylglycine. Furthermore, the 1:1 cocrystal exhibited higher aqueous solubility than the 2:1 cocrystal, despite its low hygroscopicity, as shown in Examples 5 and 6.

[0277] Example 11 : Preparation of cocrystals of N-methylglycine and fumaric acid Co-crystals of N-methylglycine and fumaric acid in various ratios (1:1, 2:1, 3:1, and 6:1) were prepared by dissolving the N-methylglycine and fumaric acid in ethanol in the corresponding ratios, followed by the procedure described in Example 1. The XRPDs of the 1:1, 2:1, 3:1, and 6:1 co-crystals are shown in Figures 20, 21, 22, and 23.

[0278] Example 12 Hygroscopicity test of cocrystal of N-methylglycine and fumaric acid 0.1 g to 0.5 g each of the 1:1, 2:1, 3:1, and 6:1 N-methylglycine cocrystals were placed in vials under ambient conditions. The weight change of each cocrystal was measured at various times, and the results are shown in Table 4 below. Table 4. Hygroscopicity study of N-methylglycine:fumaric acid cocrystal

[0279] [Table 4]

[0280] The above results suggested that the 1:1 co-crystal of N-methylglycine and fumaric acid was much less hygroscopic than the 2:1, 3:1, and 6:1 co-crystals, similar to the findings in Examples 5 and 6.

[0281] Example 13 Protective Effects of N-Methylglycine:L-Tartaric Acid Cocrystal in Mice Treated with MK-801 The purpose of this experiment was to evaluate the use of N-methylglycine (N-MG):L-tartaric acid (L-TA) cocrystal (1:1) in treating CNS disease in the MK-801 model. Animal models involving MK-801-induced hyperactivity have been widely used in the study of various neuropsychiatric disorders and in the development of assays for pathological conditions including, but not limited to, schizophrenia, bipolar disorder, attention-deficit hyperactivity disorder, obsessive-compulsive disorder, Tourette's syndrome, autism spectrum disorder, ataxia-attractant syndrome, Parkinson's disease, dementia with Lewy bodies, and senile dementia (Rubia et al., 2010; Sheppard & Bradshaw, 1999; Bent et al., 2004; Powell & Miyakawa, 2006; Nestler & Hyman, 2010; Bubeni'kava'-Vales'ova et al., 2008; Gobira et al., 2013; Lai et al., 2014; Maio et al., 2014; Sontag et al., 2010; Ding et al., 2014; Walitza et al., 2007; Finestone et al., 1982; Golimstok et al., 2011 ).

[0282] Methods and Materials: (i) Animals and housing conditions

[0283] C57BL / 6J male mice were group-housed in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal room with free access to food and water. The colony was maintained at a temperature of 22 ± 2°C on a 12 / 12-h light / dark cycle, with all behavioral testing performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months old).

[0284] (ii) Drug administration Mice were randomly assigned to six groups: Group 1: ddH2O + saline control group; Group 2: ddH2O + MK-801; Group 3: N-MG (278 mg / kg) + MK-801; Group 4: N-MG (745 mg / kg) + MK-801; Group 5: N-MG / L-TA = 1 / 1 (746 mg / kg) + MK-801; and Group 6: N-MG / L-TA=1 / 1 (2000 mg / kg) + MK-801.

[0285] Mice in groups 2–6 received acute intraperitoneal (ip) administration of 0.2 mg / kg or 0.3 mg / kg MK-801 (Sigma-Aldrich, USA) in saline 20 min before the locomotor test. Mice in groups 3–4 received acute oral (po) administration of 278 mg / kg and 745 mg / kg N-MG (3.1 mmol / kg and 8.4 mmol / kg) in saline 20 min before MK-801 administration. Mice in groups 5–6 received acute oral (po) administration of 746 mg / kg and 2000 mg / kg 1:1 cocrystal (N-MG / L-TA = 1 / 1) in saline, containing amounts equivalent to the amounts of N-MG administered to mice in groups 3–4 (3.1 mmol / kg and 8.4 mmol / kg), respectively, 20 min before MK-801 administration.

[0286] result (i) Effect of N-methylglycine:L-tartaric acid (1:1 cocrystal) on locomotor activity in MK-801-treated mice The open field test is a routine measure of novelty-induced exploratory behavior and general activity in both mice and rats. In this test, mice were placed in Plexiglas cages (47.1 cm × 25.1 cm × 20.9 cm) under a light intensity of 50–65 lux. Their spontaneous locomotor activity was measured over a 60-min period using a Photobeam Activity System Open Field (San Diego Instruments, San Diego, CA, USA). The number of beam breaks for each mouse was measured as an index of locomotor activity.

[0287] Compared to the control group (Group 1), the MK-801 group (0.2 mg / kg) showed higher locomotor activity. As shown in Figure 24, compared to the MK-801 group, the N-methylglycine groups (Groups 3 and 4) showed significantly lower locomotor activity, while the 1:1 cocrystal groups (Groups 5 and 6) showed significantly lower locomotor activity.

[0288] (ii) Effect of N-methylglycine:L-tartaric acid (1:1 cocrystal) on prepulse inhibition in MK-801-treated mice Preattentive processes tend to operate spontaneously and rapidly outside of conscious awareness, whereas deliberate attentional processes have limited resources, require effort, and operate more slowly. A common measure of preattentive processes is prepulse inhibition. This paradigm is commonly tested in mouse models of several psychiatric disorders, including, but not limited to, schizophrenia, major depressive disorder, bipolar disorder, attention deficit disorder, attention deficit hyperactivity disorder, tic disorders, obsessive-compulsive disorder, Tourette's disease, blepharospasm, post-traumatic stress disorder, panic disorder, Asperger's disorder, mild Alzheimer's dementia, Lewy body disease, Huntington's disease, personality disorders, nocturnal enuresis, and non-epileptic seizures (see McAlonan et al., 2002; Braff et al., 2001; Giakoumaki et al., 2007; Ueki et al., 2006; Perriol et al., 2005; Ludewig et al., 2002; Castellanos et al., 1996; Cadenhead et al., 2000; Matsuo et al., 2017; Lai et al., 2014), because such disorders manifest in a manner similar to human symptoms.

[0289] Prepulse inhibition was measured as an index of sensorimotor gating using an SR-LAB startle stimulator (San Diego Instruments, San Diego, CA, USA). Each session consisted of 64 trials over a 5-minute cumulative period, divided into four blocks, under 65 dB background noise. Pulse-only (PA) trials consisted of a 40-ms, 120 dB white noise burst. Prepulse (PP) plus pulse trials consisted of a 20-ms white noise prepulse stimulus at 71 dB (PP6), 75 dB (PP10), or 83 dB (PP18) for 100 ms, followed by a 40-ms 120 dB pulse. No-stimulus (NS) trials consisted of background noise alone. The initial and final blocks each consisted of six PA trials. The two intermediate blocks consisted of PA, PP plus pulse, and NS trials. The trials were separated by an average inter-trial interval of 15 seconds (varied between 10 and 20 seconds) and presented in a pseudorandomized manner. The percent prepulse inhibition (PPI) was evaluated using the following formula: %PPI = 100 × [(PA score) - (pp-P score)] / (PA score), where PA score was the average PA value in the middle block.

[0290] Compared to the control group (Group 1), the MK-801 (0.3 mg / kg) group induced robust prepulse inhibition deficits at all prepulse intensities. The high-dose 1:1 cocrystal (2000 mg / kg) group exhibited significantly greater rescue / protection against the MK-801-induced deficits in prepulse inhibition at all prepulse intensities. Such results were not observed in either the N-methylglycine group or the low-dose 1:1 cocrystal group (746 mg / kg), as shown in Figure 25.

[0291] Example 14 Effects of N-methylglycine:L-tartaric acid (N-MG / L-TA 1:1 cocrystal) and N-methylglycine:L-tartaric acid (N-MG / L-TA 2:1 cocrystal) on locomotion in MK-801-treated mice The open field test is a routine measure of novelty-induced exploratory behavior and general activity in both mice and rats. In this test, mice were placed in Plexiglas cages (47.1 cm × 25.1 cm × 20.9 cm) under a light intensity of 50–65 lux. Their spontaneous locomotor activity was measured over a 60-min period using a Photobeam Activity System Open Field (San Diego Instruments, San Diego, CA, USA). The number of beam breaks for each mouse was measured as an index of locomotor activity.

[0292] Mice were treated with N-methylglycine ("N-MG"), N-MG / L-TA 1:1 cocrystal, or N-MG / L-TA 2:1 cocrystal under the MK-801 model conditions as indicated: N-MG (745 mg / kg) + MK-801; N-MG / L-TA=1 / 1 (2000 mg / kg) + MK-801; N-MG (1078 mg / kg) + MK-801; N-MG / L-TA=2 / 1 (2000 mg / kg) + MK-801. MK-801 treatment conditions were as described in Example 13. The total N-MG content administered to mice treated with the cocrystal was the same as that administered to mice treated with N-MG.

[0293] Animals treated with 745 mg / kg and 1078 mg / kg N-methylglycine showed reduced locomotor activity with recovery rates of 45% and 63%, respectively. In contrast, animals treated with N-MG / L-TA cocrystals showed recovery rates of 65% and 93% for the 1:1 and 2:1 cocrystals, respectively, which are much higher than those treated with N-MG. The 2:1 cocrystal also showed a higher recovery rate than the 1:1 cocrystal, indicating a more favorable therapeutic effect, as shown in Figure 26.

[0294] Example 15 Effect of different dose levels of N-methylglycine:L-tartaric acid (2:1 cocrystal) on locomotion in MK-801-treated mice Mice were treated with N-MG or the 2:1 co-crystal as described in Example 14 above in combination with MK-801 according to the following conditions: - Saline solution; - saline + MK-801 (0.2 mg / kg MK-801); - N-MG (539 mg / kg)+MK-801 (0.2 mg / kg); - N-MG (1078 mg / kg)+MK-801 (0.2 mg / kg); - N-MG / L-TA=2 / 1_1000MK-801 (1000 mg of N-MG / L-TA 2:1 cocrystal containing 539 mg of N-MG) + MK-801 (0.2 mg / kg); and - N-MG / L-TA=2 / 1_2000MK-801 (2000 mg of N-MG / L-TA 2:1 cocrystal containing 1078 mg / kg of N-MG) + MK-801 (0.2 mg / kg).

[0295] The procedures for MK-801 treatment and measurement of locomotor activity (represented by the number of beam breakers) were as provided in Example 13 above. As shown in Figure 27, MK-801 treatment enhanced locomotor activity in the mouse model; both N-MG and the cocrystals reduced locomotor activity induced by MK-801. The cocrystals, especially the 2:1 cocrystal, resulted in a significantly greater reduction in locomotor activity compared to N-MG in MK-801-treated mice.

[0296] Example 16 Effect of N-methylglycine:L-tartaric acid (2:1 cocrystal) compared to N-methylglycine on recovery rate in MK-801-treated mice Mice were treated with N-MG or N-MG / L-TA 2:1 cocrystal in combination with MK-801 according to the following conditions: - N-MG (539 mg / kg)+MK-801 (0.2 mg / kg); - N-MG (1078 mg / kg)+MK-801 (0.2 mg / kg); - N-MG / L-TA=2 / 1_1000MK-801 (1000 mg of N-MG / L-TA 2:1 cocrystal containing 539 mg of N-MG) + MK-801 (0.2 mg / kg); and - N-MG / L-TA=2 / 1_2000MK-801 (2000 mg of N-MG / L-TA 2:1 cocrystal containing 1078 mg / kg of N-MG) + MK-801 (0.2 mg / kg).

[0297] The procedures for MK-801 treatment and measurement of locomotor activity recovery are as described above in Example 13. As shown in Figure 28, mice treated with N-MG / L-TA 2:1 cocrystal showed a significantly higher recovery rate of locomotor activity compared to N-MG at two doses in MK-801-treated mice.

[0298] Example 17 Protective effect of N-methylglycine:L-tartaric acid cocrystal in MK-801-treated mice The purpose of this experiment was to evaluate the use of N-methylglycine (N-MG):L-tartaric acid (L-TA) cocrystal (2:1) in treating CNS disorders using the MK-801 mouse model described herein according to the following conditions: - Saline solution; - saline + MK-801 (0.2 mg / kg MK-801); - N-MG (1078 mg / kg)+MK-801 (0.3 mg / kg); - N-MG / L-TA = 2 / 1_2000MK-801 (2000 mg of N-MG / L-TA 2:1 cocrystal containing 1078 mg / kg of N-MG) + MK-801 (0.3 mg / kg).

[0299] The procedures for MK-801 treatment and measurement of prepulse inhibition protective effects are as described in Example 13. As shown in Figure 29, MK-801-induced prepulse inhibition in mice treated with the above and MK-801-induced prepulse inhibition were rescued by both N-MG and N-MG / L-TA 2:1 cocrystal. Furthermore, the same doses of N-MG and N-MG / L-TA 2:1 cocrystal showed significantly higher rescue / protection effects against MK-801-induced prepulse inhibition compared to N-MG.

[0300] Example 18 Spatial memory retrieval effects of N-methylglycine:L-tartaric acid cocrystal in MK-801-treated mice Spatial learning and memory Mice were tested in the Barnes maze to assess their spatial learning and memory, as previously described (Barnes, J. Comp. Physiol. Psychol., 93(1):74-104

[1979] ). The testing apparatus consisted of a circular Plexiglas® plate (100 cm diameter) elevated above the reference surface (50 cm above the floor) with 20 holes (7 cm diameter, 7 cm spacing) evenly spaced around the perimeter. Mice were trained on the plate to identify an escape box hidden behind a target hole, designed similarly to the hidden platform in the Morris water maze. The location of the target hole was selected for each mouse but randomized across mice. Mice were initially placed in the center of the plate, which was covered by an opaque cylinder. 10 seconds after the start of the test, the cylinder was removed, and both the unpleasant tone (440 Hz, 85 dB) and the light (100 lux) were turned on. Mice were trained to follow peripheral visual cues (cues) to enter the target hole and escape from an unpleasant tone for three training trials per day over three consecutive days. Spatial memory was measured by a "probe trial." All training and probe trials were videotaped for 3 minutes. The escape latency of the training trials and the proportion of time spent in the various quadrants (target, left, right, and contralateral) during the probe trials were then analyzed.

[0301] Mice were tested in the Barnes maze to evaluate the use of N-methylglycine (N-MG):L-tartaric acid (L-TA) cocrystal (2:1) in treating CNS disorders using the MK-801 mouse model described herein according to the following conditions: - N-MG (1078 mg / kg)+MK-801 (0.2 mg / kg); - N-MG / L-TA=2 / 1_2000MK-801 (2000 mg of N-MG / L-TA 2:1 cocrystal containing 1078 mg of N-MG) + MK-801 (0.2 mg / kg).

[0302] The procedure for MK-801 treatment is as described in Example 13. As shown in Figure 30, mice co-treated with MK-801 and N-MG / L-TA 2:1 cocrystal exhibited superior spatial memory on day 3 as measured by latency compared to mice co-treated with MK-801 and N-MG.

[0303] Equivalence and Scope In the claims, unless otherwise indicated or the context clearly dictates otherwise, articles such as "a," "an," and "the" refer to one or more. Unless otherwise indicated or the context clearly dictates otherwise, a claim or description including "or" between one or more members of a group is considered to be valid if one, multiple, or all members of the group are present in, employed in, or otherwise relevant to a particular product or process. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a particular product or process. The invention also includes embodiments in which multiple or all members of the group are present in, employed in, or otherwise relevant to a particular product or process.

[0304] Furthermore, the present invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the enumerated claims are introduced into another claim. For example, any claim that depends on another claim can be modified to include one or more limitations found in any other claim that depends from the same base claim. When elements are provided as a list, e.g., in Markush format, each subgroup of those elements is also disclosed, and any element may be removed from the group. In general, when an invention or aspect of the invention is referred to as comprising certain elements and / or features, some features or aspects of the invention consist of or consist essentially of such elements and / or features. For purposes of brevity, those aspects have not been specifically described herein instead. Also, note that the terms "comprise" and "contain" are intended to permit the inclusion of additional elements or steps. When ranges are given, the endpoints are included. Furthermore, unless otherwise indicated or clearly diverging from the context or the understanding of one of ordinary skill in the art, numerical values expressed as ranges can take any specific value within the range recited in various embodiments of the invention or subranges within the range recited in various aspects of the invention, down to one-tenth of the unit of the lower limit of that range.

[0305] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. In the event of a conflict between an incorporated reference and the present specification, the present specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be expressly excluded from any one or more of the claims. Such embodiments are deemed known to those of ordinary skill in the art and may be excluded even if the exclusion is not explicitly set forth herein. Any particular embodiment of the present invention may be excluded from any claim for any reason, whether related to the existence of prior art or not.

[0306] Those skilled in the art will be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the embodiments of the invention described herein is not limited to the above description, but rather is set forth in the appended claims. Those skilled in the art will appreciate that various changes and modifications to the description herein can be made without departing from the spirit or scope of the invention, as defined in the following claims.

Claims

1. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is D-tartaric acid; the molar ratio between the substituted glycine and the coformer in the co-crystal is 1:1; and The co-crystal 【Table 1】 and an exothermic peak corresponding to a melting point of 139°C.

2. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is L-tartaric acid; the molar ratio between the substituted glycine and the coformer in the co-crystal is 1:1; and The co-crystal 【Table 2】 and an exothermic peak corresponding to a melting point of 138°C.

3. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is L-tartaric acid; the molar ratio between the substituted glycine and the coformer in the co-crystal is 2:1; and The co-crystal is 【Table 3】 The co-crystal has a powder X-ray diffraction pattern depicted in

4. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is DL-tartaric acid; the molar ratio between the substituted glycine and the coformer in the co-crystal is 1:1; and The co-crystal 【Table 4】 and an exothermic peak corresponding to a melting point of 120°C.

5. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is fumaric acid; the molar ratio between the substituted glycine compound and the coformer in the cocrystal is 1:1; and The co-crystal 【Table 5】 The co-crystal has a powder X-ray diffraction pattern depicted in

6. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is fumaric acid; the molar ratio between the substituted glycine compound and the coformer in the cocrystal is 2:1; and The co-crystal 【Table 6】 The co-crystal has a powder X-ray diffraction pattern depicted in 7. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is fumaric acid; the molar ratio between the substituted glycine compound and the coformer in the cocrystal is 3:1; and The co-crystal 【Table 7】 The co-crystal has a powder X-ray diffraction pattern depicted in 8. A co-crystal of a substituted glycine compound and a coformer, comprising: the substituted glycine is N-methylglycine; the coformer is fumaric acid; the molar ratio between the substituted glycine compound and the coformer in the cocrystal is 6:1; and The co-crystal 【Table 8】 The co-crystal has a powder X-ray diffraction pattern depicted in

9. A composition comprising an effective amount of the co-crystal of any one of claims 1 to 8 and a carrier.

10. 10. The composition of claim 9, wherein the composition is a pharmaceutical composition, a nutraceutical composition, a health food, or a medical food.

11. 11. A composition for use in treating or reducing the risk of a neuropsychiatric disorder in a subject, the composition comprising a therapeutically effective amount of a cocrystal of any one of claims 1 to 8 or the composition of claim 9 or claim 10.

12. 12. The composition for use of claim 11, wherein the neuropsychiatric disorder is selected from the group consisting of schizophrenia, psychosis, Alzheimer's disease, dementia, frontotemporal dementia, mild cognitive impairment, benign amnesia, closed head trauma, autism spectrum disorder, Asperger's disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, tic disorder, childhood learning disability, premenstrual syndrome, depression, suicidal ideation and / or behavior, dysthymic disorder, bipolar disorder, anxiety disorder, post-traumatic stress disorder, chronic pain, eating disorders, addictive disorders, personality disorders, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis.

13. 10. Use of a therapeutically effective amount of the cocrystal of any one of claims 1 to 8 for the manufacture of a medicament for treating or reducing the risk of a neuropsychiatric disorder in a subject.

14. A method for preparing the co-crystal according to any one of claims 1 to 8, comprising the steps of: (i) mixing a substituted glycine compound and a coformer in a solvent at a temperature of 40 to 110°C to form a saturated solution, wherein the substituted glycine compound and the coformer are in a molar ratio of 10:1 to 1:10; (ii) further heating the solution at a temperature of 40 to 110°C for 1 to 10 hours; (iii) cooling the solution to a temperature of 4 to 30°C for 10 to 36 hours to allow for the formation of the co-crystal; and (iv) Recovering the co-crystal formed in (iii). The method includes:

Images